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Abstract

EFFECTS OF MU OPIOID RECEPTOR AGONISTS ON INTRACRANIAL SELFSTIMULATION IN THE ABSENCE AND PRESENCE OF PAIN IN RATS
By: Ahmad A. Altarifi, Ph.D.
A dissertation submitted in partial fulfillment of the requirements for the degree of
Philosophy at Virginia Commonwealth University
Virginia Commonwealth University, 2013
Director: S. Stevens Negus, Ph.D.
Professor, Department of Pharmacology and Toxicology

Pain is a significant health problem. Mu opioid receptor agonists are used clinically as
analgesics, but their use is constrained by high abuse liability. Intracranial self-stimulation
(ICSS) is a preclinical behavioral procedure that has been used to assess abuse potential of
opioids, and drug-induced facilitation of ICSS is interpreted as an abuse-related effect. ICSS
can also be used as a behavioral baseline to detect affective dimensions of pain. Specifically,
pain-related depression of ICSS can model pain-related depression of behavior and mood, and
drug-induced blockade of pain-related ICSS depression can serve as a measure of affective
analgesia. This dissertation used mu agonists that vary in efficacy at the mu receptor
(methadone> fentanyl> morphine> hydrocodone> buprenorphine> nalbuphine) and compared
their effects on ICSS in the absence (phase one) or presence (phase 2) of pain. Adult male
Sprague-Dawley rats were equipped with intracranial electrodes targeting the medial forebrain
bundle and trained to lever press for brain stimulation. Different frequencies of stimulation
maintained a frequency-dependent increase in ICSS rates, and permitted detection of both rate-
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increasing and rate-decreasing treatment effects. During phase 1, medium- and high-efficacy
mu agonists produced initial rate-decreasing effects, followed by abuse-related rate-increasing
effects at later time points. Repeated morphine administration produced tolerance to its own
rate-decreasing effects, cross-tolerance to rate-decreasing effects of other mu agonists, and
enhanced expression of rate-increasing effects. Low efficacy mu agonists only produced rateincreasing effects, which were enhanced after repeated morphine. These results suggest that
previous opioid exposure increases expression of abuse-related facilitation of ICSS by mu
agonists regardless of efficacy. During phase 2, intraperitoneal administration of lactic acid
(1.8%) served as a noxious stimulus to depress ICSS. All mu agonists blocked acid-induced
depression of ICSS at doses similar to those that facilitated ICSS in the absence of pain. A
higher intensity noxious stimulus (5.6 % acid) produced further depression of ICSS and reduced
the antinociceptive potency of both methadone and nalbuphine. Morphine antinociception was
resistant to tolerance in the assay of acid-depressed ICSS. Overall, these results provide a
basis for comparing determinants of abuse-related opioid effects in the absence of pain with
their affective analgesic effects in the presence of pain.

ix

CHAPTER ONE
Introduction and Background

1.1.

Opioid background
Opioids are a group of drugs that are widely used in clinical and veterinary

medicine for multiple purposes. The prototype opioid morphine is a naturally occurring
alkaloid that can be extracted from the juice that leaks from the poppy plant, Papaver
somniferum. Many synthetic and semi-synthetic analogues have been synthesized in
the last century. The origin of human use of opioids is not exactly known, but there is
some evidence that opioids were used by the Greeks, Indians, and Sumerians
(Brownstein, 1993). They extracted the juice (called opium) from the poppy seed pods
and used it as a euphoriant in religious rituals, as a poison, and medicinally to treat pain
and other illnesses (Trescot et al., 2008). In 1804, a German scientist isolated the main
active ingredient in opium: morphine (Klockgether-Radke, 2002). The name is derived
from Morpheus, after the Greek god of dreams. Later, other naturally occurring opioids
were identified, and pharmaceutical companies initiated their sales of morphine. The
high abuse potential of morphine encouraged researchers to synthesize compounds
that resemble morphine in its beneficial properties, but with lower abuse potential.
These compounds have been classified as “semi-synthetic” (i.e. derived from morphine
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or other alkaloids found in opium) or “synthetic” (structurally distinct from morphine).
Heroin (first synthesized in 1874) was the first semi-synthetic opioid, and despite its
popularity at the beginning as a substitute to morphine, it had more potential of being
abused and misused by patients. This led to an increase in research focusing on
synthesizing alternative compounds to morphine that might produce fewer side effects
but maintaining analgesic properties. Table 1.1 summarizes the opioid ligands that were
used in this project.

Table 1.1. Classification and date of discovery for mu opioid agonists that are
used in this project

Ligand

Classification

Date of discovery

Methadone

Synthetic

1937

Fentanyl

Synthetic

1960

Morphine

Natural

1804

Hydrocodone

Semi-synthetic

1920

Buprenorphine

Semi-synthetic

1980s

Nalbuphine

Semi-synthetic

1960s

Naltrexone

Semi-synthetic

1963

Currently, opioids are among the most effective and reliable tools available to
clinicians for the treatment of strong pain associated with acute trauma (e.g. surgery,
burns) or chronic pain associated with cancer and other illnesses (Gutstein and Akil,
2005). For example, recent surveys indicate that opioid analgesics account for more
than 10% of all prescription drug sales in the U.S. (Max, 2003), and four of the 10 most
prescribed drugs in 2005 were opioid analgesics
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(http://www.rxlist.com/script/main/art.asp?articlekey=79509). In 2009, Vicodin (trade
name for hydrocodone containing acetaminophen) was the most prescribed drug in the
U.S. (IMS National Prescription Audittm). These statistics show the impact of pain on
society, and the important role that opioids can play in this clinically relevant topic.
Despite their clinical importance and significant role in decreasing the “feel of
pain”, physicians are cautious in prescribing narcotics due to some unwanted effects
including respiratory depression, nausea and vomiting, constipation, tolerance
development, interaction with other drugs, and perhaps most importantly, abuse liability
(Inturrisi, 2002; Bhamb et al., 2006). For instance, oxycodone, fentanyl and morphine
prescriptions were increased by 50, 150, and 60% between 1999 and 2002,
respectively (Compton and Volkow, 2006), and during the same period, there was a
91.2% increase in deaths due to opioid poisoning (Paulozzi et al., 2006). More recently,
the Substance Abuse and Mental Health Services Administration (SAMHSA) national
survey in 2011 showed that 4.5 million Americans used pain relievers for illicit purposes
during the past month of the survey (SAMHSA, 2011). The illicit use of prescription
analgesics was second only to marijuana in prevalence of illicit drug use. The same
survey showed that heroin addiction almost doubled between the years 2007-2011. In
2005, the estimated cost of abusing prescription opioids in the United States was about
9.5 billion dollars (Birnbaum et al., 2006). This problem also extends to other regions in
the world such as Europe and Jordan (Casati et al., 2012). Thus, the above statistics
suggest two essential problems:
1) The increased use of opioids in the last 2 decades highlights the failure to find
a better and safer analgesic that can replace opioids in the clinic, and
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2) Science has failed to solve the secrets that underlie the mechanism of opioid
addiction, and hence the abuse potential of opioids is hardly avoidable.
Thus, although much research and effort has been devoted to solve the above
problems, research has so far failed to discover effective alternatives to opioid
analgesics or to adequately understand the neurobiology of pain or addiction. This
project proposes a new assay to measure “pain” in laboratory animals, and this may
improve predictive validity with clinical results. This issue will be discussed thoroughly in
section 1.3.

1.2.

Opioid receptors: subtypes / signaling / mechanism of action
After the discovery of morphine and development of novel semi-synthetic and

synthetic opioids, the next advance in the opioid field was the discovery of their
mechanism of action. The stereospecificity of opioid effects suggested the existence of
some specific sites (i.e. receptors) that could be targeted after opioid administration
(Goldstein et al., 1971). Using a radio-labeled opioid antagonist, the first evidence of the
presence of these receptors in the nervous system was reported in 1973 (Pert and
Snyder, 1973; Simon et al., 1973; Terenius, 1973). The presence of these receptors
encouraged researchers to look for opioid-like endogenous compounds, and the first
was identified in 1975 (Hughes, 1975; Hughes et al., 1975). Further investigations
identified three major subtypes of opioid receptors: Mu, Delta, and Kappa. These
receptors were cloned in the last 2 decades (Evans et al., 1992; Chen et al., 1993;
Meng et al., 1993). A fourth type have been suggested more recently, the opioid
receptor-like 1 (ORL1) receptor, and its pharmacology and significance are under
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investigation (Meunier et al., 1995). Further pharmacological characterization has
revealed that mu opioid receptors mediate most of morphine’s desired effects, such as
analgesia, as wells as undesired effects, such as abuse potential. One goal of the
current project is to better understand the behavioral profile of mu agonist-induced
abuse-related and analgesic effects, and the relationship between these effects.
Characterization of this behavioral profile can then provide a foundation for research on
mechanisms of those effects and strategies to dissociate them.
Opioid receptors are classified as G-protein coupled receptors (GPCRs). As with
all GPCRs, these 7-transmembrane protein receptors bind extracellulary with the
receptor ligand (such as morphine), and intracellularly with a complex of proteins (Gprotein) consisting of three subunits: Alpha, Beta and Gamma. The alpha subunit in turn
binds to Guanosine Diphosphate (GDP) during the inactive state of the receptor (hence
the letter “G” in GPCR). Upon activation of the receptor (e.g. binding of an agonist),
guanosine triphosphate (GTP) replaces GDP at the guanine nucleotide binding site, and
GDP dissociates from the alpha subunit. This exchange promotes dissociation of all
three subunits from the receptor, and also enhances the dissociation of alpha/GTP
complex from the beta/gamma complex. Upon dissociation, both complexes can
activate or deactivate different downstream targets such as enzymes, proteins, and/or
transcription factors. The alpha subunit has GTPase activity that hydrolyzes GTP to
GDP to promote rebinding with the beta/gamma complex and the receptor to terminate
signaling (for review, (Lopez-Ilasaca et al., 1997)). Figure 1.1 summarizes the GPCR
receptor activation/deactivation cycle (adapted from
http://commons.wikimedia.org/wiki/File:GPCR-Zyklus.png).
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Figure 1.1. Sequence of events following the binding of a ligand to a G-protein
coupled receptor. Upon binding of an agonist (step 2), Guanosine Triphosphate (GTP)
replaces GDP at the guanine nucleotide binding site, and GDP dissociates from the
alpha subunit (step 3 and 4). This exchange promotes dissociation of all three subunits
from the receptor, and also enhances the dissociation of alpha/GTP complex from the
beta/gamma complex. Upon dissociation, both complexes can activate or deactivate
different downstream targets such as enzymes, proteins, and/or transcription factors.
The alpha subunit has GTPase activity that hydrolyzes GTP to GDP (step 6) to promote
rebinding with the beta/gamma complex (Step 1).
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GPCRs are classified depending on the alpha subunit subtype. In the case of
opioid receptors, they are linked to Gi/o. After a mu receptor agonist binds to the mu
receptor, targets of the GTP-bound alpha subunit and free beta/gamma complex
include:
-

the efflux of potassium through G protein-coupled inwardly-rectifying
potassium channels (GIRKs) (Lober et al., 2006),

-

inhibition of adenylate cyclase (and the subsequent decrease in intracellular
cyclic-Adenosine Monophosphate (cAMP)) (Murthy and Makhlouf, 1996),

-

inhibition of N-type voltage-dependent calcium channels (Yu et al., 1990;
Soldo and Moises, 1998; Ikeda et al., 2000), and

-

stimulation of mitogen-activated protein kinase (MAPK) pathway.

Overall, these events result in reduced neuronal cell excitability leading to a
reduction in transmission of nerve impulses along with an inhibition of neurotransmitter
release as summarized in figure 1.2 (McDonald and Lambert, 2005; Trescot et al.,
2008).

Figure 1.2. Summary of
downstream signaling
and second messengers
coupled to an active
GPCR/Gi/o. (McDonald
and Lambert, 2005)
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Repeated drug administration (such as daily administration of morphine) has
been associated with two processes involving neural adaptation: tolerance and
sensitization. Tolerance is a term used to describe the need for an increasing dose to
achieve the same effect (Nestler, 1996). Possible mechanisms that contribute to opioid
tolerance include receptor desensitization/internalization. Both processes may be
involved in opioid tolerance after acute (i.e. after single opioid injection) or repeated
opioid administration. The molecular mechanism for desensitization starts with
phosphorylation of the mu receptor by G-protein receptor kinase (GRK), followed by
recruitment of beta-arrestin, which uncouples the receptor from its downstream
signaling cascade (Gainetdinov et al., 2004; DeWire et al., 2007; Nagi and Pineyro,
2011). Under some circumstances (depending on drug dose and drug efficacy at the
receptor), these events of receptor phosphorylation and beta-arrestin binding may lead
eventually to receptor internalization (or downregulation) (Borgland et al., 2003). With
both desensitization and downregulation, the density of “functional” opioid receptor is
decreased, and that will diminish opioid effects, although receptor internalization may
also permit recycling of functional receptors back into the membrane. Figure 1.3
summarizes receptor desensitization and internalization after binding of a ligand to
GPCR receptor.
The other phenomenon that is also associated with repeated opioid
administration is behavioral sensitization. It involves a progressive and enduring
enhancement in the motor stimulant effect elicited by a subsequent drug challenge
(Vanderschuren and Kalivas, 2000). Mechanisms of this phenomenon may include
cellular adaptations in specific neural populations such as up-regulation of AMPA
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receptor subunit GluR1 in the VTA (Fitzgerald et al., 1996; Carlezon et al., 1997) and
induction of delta-FosB in the NA and amygdala (Zachariou et al., 2006; Kaplan et al.,
2011)

Figure 1.3. Sequence of events for desensitization and internalization of
mu-opioid receptor after binding of an agonist to the receptor. (adapted
from (Borgland et al., 2003).
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Mu opioid receptors have been localized extensively throughout the brain.
Some of these areas include nucleus accumbens (NA), periaquiductal gray
(PAG), ventral tegmental area (VTA), rostroventral medulla (RVM), amygdala,
and thalamus (Mansour et al., 1987; Dilts and Kalivas, 1989; Mansour et al.,
1994; Pinto et al., 2008). Although mu receptors have been identified in other
locations, the above brain areas are essential for analgesic and rewarding effects
of opioids. One procedure to study these effects is through direct administration
of the agonist into a specific brain region. For instance, administration of mu
agonists into RVM, PAG, VTA, or amygdala was sufficient to induce
antinociception in preclinical assays of pain-stimulated behavior (discussed later)
as their dependent measure (Bodnar et al., 1988; Manning et al., 1994; Borszcz,
1995; Helmstetter et al., 1995; Fields, 2000; Hurley et al., 2003). Likewise, direct
administration of mu agonists into NA or VTA was sufficient to maintain opioid
self-administration in animals (Olds, 1982; Welzl et al., 1989; Devine and Wise,
1994). Also, local injection of mu agonists in the VTA (Phillips and LePiane,
1980; Zangen et al., 2002), but not into the NA (Olmstead and Franklin, 1997),
produced conditioned place preference (CPP), which is an assay used to
measure abuse-related drug reward in animals. These findings suggest that
antinociceptive and abuse-related effects of mu agonists can be localized, for the
most part, in separate brain areas, but they could be integrated and merged in
others, such as the VTA.
So far, the VTA appears to be an especially interesting site for convergent
antinociceptive and rewarding effects of mu agonists. The VTA is the site where the
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mesolimbic dopaminergic neurons cell bodies are located. These neurons project to the
NA, and stimulation of this pathway is often correlated with the rewarding effect of
different reinforcers, such as food, sex, and drugs of abuse. In the field of opioid
pharmacology, direct mu opioid agonist administration into the VTA excites
dopaminergic neurons (Matthews and German, 1984). Further studies indicated that
posterior VTA seems to be more relevant for mu agonist-induced reward, such that mu
receptors are present in a higher density in posterior VTA than anterior VTA (Mansour
et al., 1995), and direct microinjection of mu agonists in the posterior VTA produced
more robust acquisition of drug self-administration, conditioned place preference (CPP),
and locomotor activity (Zangen et al., 2002). GABAergic neurons are also present in a
high density in the posterior VTA, and opioid receptors are co-localized on these
inhibitory, non-dopaminergic neurons (Garzon and Pickel, 2001; Svingos et al., 2001).
From these findings, it has been suggested that mu opioid agonists activate
dopaminergic neurons by decreasing the inhibitory influence of the caudally located
GABAergic cells, a term called disinhibition (Johnson and North, 1992).
In summary, mu opioid receptors have been localized in widespread areas in the
brain. These receptors are GPCRs, and they are linked to the inhibitory G-protein
subtype, Gi/o. Mu opioid receptors are located on inhibitory GABAergic interneurons in
the VTA, and once they bind to these cells, they attenuate GABA-mediated inhibition of
dopaminergic neurons located also in the VTA. The final output is an increase in the
dopaminergic neurons firing in the mesolimbic pathway, and an increase in dopamine
release in the NA.
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1.3.

Pain: significance, neurobiology, and animal models of pain
Pain is a significant and pervasive public health problem. It has been estimated

that 42% of US adults experience pain in their daily lives (Lethbridge-Cejku et al., 2004),
and that this pain accounts for more than 20% of all medical visits and approximately 50
million lost work days per year (Max, 2003). The total cost to the US economy in painrelated healthcare and disability is estimated at over $100 billion per year (Society,
2000).
Pain is defined as “an unpleasant sensory and emotional experience associated
with actual or potential tissue damage, or described in terms of such damage” (pain,
1979). Noxious stimuli that produce tissue damage and inflammation activate primary
afferent nociceptors located in the peripheral nervous system. These pseudounipolar
neurons have their cell bodies in the dorsal root ganglion, with a peripheral terminal
directed toward the skin, muscles, or visceral tissues, and a central terminal directed to
the dorsal horn of the spinal cord. They transmit damage signals from peripheral organs
to the centrally located second order neurons, also called spinothalamic neurons. These
neurons have their cell bodies in the spinal cord, and after they cross the midline, they
project to thalamic nuclei, where they synapse with tertiary neurons in the thalamus.
Axons of the tertiary neurons project to different cortical areas such as somatosensory
cortex I (SI), somatosensory cortex II (SII), anterior cingulate cortex (ACC) and insula.
Limbic regions receive pain information through from two general sources. First,
secondary neurons originating in the spinal cord also send bottom-up projections to
brainstem areas, such as PAG, RVM, hypothalamus, and parabrachial nucleus (PBN).
Some of these areas (e.g. the PBN) send projections to limbic areas such as the VTA
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(Giesler et al., 1979; Cliffer et al., 1991; Coizet et al., 2010). Second, cortical areas such
as SII, ACC and insula send top-down projections to limbic areas, such as VTA, NA,
and amygdala. Thus, limbic areas such as VTA, NA, and amygdala receive nociceptive
input via two routes: a ventral pathway that is mediated by brain stem areas such as
PBN, and a dorsal pathway that is mediated by corticolimbic connections. Moreover,
neurons in the PAG send projections to the RVM and dorsolateral pontine tegmentum
(DLPT), and both of them send descending projections back to the spinal cord for
further modulation of nociceptive information (Mantyh and Peschanski, 1982; Basbaum
and Fields, 1984). Figure 1.4 summarizes some of these connections that are of interest
to the current document. These connections have consolidated the view that pain is a
complex experience encompassing sensory, affective and cognitive elements (Zubieta
et al., 2001; Neugebauer et al., 2009).
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Figure 1.4. Simplified cartoon showing major pain pathways and
connections between them inside the nervous system. Arrows indicate the
direction of signal between regions. Some areas have reciprocal
connection. Asterisks indicate that mu opioid receptors have been
localized in that area. ACC: anterior cingulate cortex; Amg: Amygdala;
DLPT: dorsolateral pontine nucleus; DRG: dorsal root ganglion; NA:
nucleus accumbens; PAG: periaqueductal gray; PBN: parabrachial
nucleus; PN: primary nociceptors; RMTg: rostromedial tegmentum; RVM:
rostroventral medulla; SI, II: Sensory area 1 and 2; VTA: ventral tegmental
area.
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Analgesia is defined as absence of pain in response to stimulation that would
normally be painful (International Association for the Study of Pain, 1994). Despite
recent advances in research on pain mechanisms and analgesic drug development,
there has been little evolution in the types of drugs used to treat pain. For decades, the
most widely used analgesics have included mu opioid agonists such as morphine, antiinflammatory steroids such as cortisone, and non-steroidal anti-inflammatory drugs
(NSAIDs) such as aspirin. As mentioned before, opioids are still the drug of choice over
other options to treat severe, chronic types of pain.
Pain is essentially a subjective experience, and its existence in humans is
typically assessed by verbal report. This report is usually guided by a scale that ranges
from 0-10, with “0” indicating “no pain” and “10” indicating “worst pain imaginable.”
Alternatively, patients can complete a questionnaire that provides added verbal detail to
their pain perception. An example of such a questionnaire is the Brief Pain Inventory
(BPI) (Daut et al., 1983), which provides information on the intensity of pain as well as
the degree to which pain interferes with function. The BPI also asks questions regarding
pain relief, pain quality, and patient's perception of the cause of pain.
In preclinical settings, assays of animal behavior have played a key role in
research on the neurobiology of pain and development of analgesic drugs (Negus et al.,
2006). These preclinical assays share two common elements: (a) a set of independent
variables implemented with the intent of producing a pain state (i.e. noxious stimuli),
and (b) a dependent measure of behavior interpreted as evidence of that pain state. A
noxious stimulus can be chemical, mechanical, thermal, or electrical in modality. In all
these cases, application of the noxious stimulus is intended to produce “pain,” and
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changes in behavior produced by the noxious stimulus are interpreted as evidence of
“pain.” Drugs or other treatments can then be evaluated for their effects on expression
of the pain-related behavior. The behavioral outcomes usually fall into one of the
following two categories:
1)

Pain-stimulated behaviors: include behaviors that increase in rate, frequency or
intensity after a noxious stimulus. These include, but are not limited to,
withdrawal reflexes from escapable stimuli (e.g. tail withdrawal after immersion of
the tail into water heated to a noxious temperature), withdrawal-like behaviors
from inescapable stimuli (e.g. stretching/writhing elicited by intraperitoneal (IP)
injection of dilute acids or chemical irritants), and vocalization;

2)

Pain-depressed behaviors: include behaviors that decrease in rate, frequency or
intensity after a noxious stimulus. Examples of this type of behavior include
depression of feeding, locomotion, and operant responding, sleep and others.

Antinociception in assays of pain-stimulated behavior are indicated by druginduced decreases in the target behavior. However, exclusive reliance on painstimulated behaviors to evaluate effects of opioids or other candidate analgesics is
problematic for several reasons (Negus et al., 2006). Perhaps most importantly, druginduced decreases in pain-stimulated behavior can be produced not only by a selective
reduction in sensory sensitivity to the noxious stimulus (i.e. true analgesia) but also by
nonselective effects such as motor impairment (resulting in “false positive” effects).
Another drawback of relying on pain-stimulated behaviors is the lack of face validity of
these behaviors with problematic dimensions of clinical pain. Noxious stimuli can elicit
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withdrawal reflexes and other pain-stimulated behaviors in humans, and there are
clinical instances (e.g. surgery) in which it is desirable to reduce these behaviors.
However, clinical suppression of pain-stimulated behaviors is usually managed with
transient exposure to anesthetics, and long-term suppression of pain-stimulated
behaviors can increase risk of injury by preventing adaptive withdrawal responses from
noxious stimuli. Clinically problematic pain, by comparison, is often expressed as
functional impairment and depression of behavior and mood, and the goal of treatment
is to normalize function and mood. As mentioned earlier, the Brief Pain Inventory is one
instrument that measures the impact of pain conditions on quality of life, such as
general activity, mood, walking ability, normal work, sleep, and social activity. Most of
these behaviors are often depressed during clinically relevant pain conditions, and
effective analgesics will reverse this depression.
In contrast to pain-stimulated behaviors, antinociception in assays of paindepressed behavior is indicated by an increase in the target behavior, and as a result,
these assays are not vulnerable to false-positive effects of drugs that produce motor
impairment. Assays of pain-depressed behavior may also add value in analgesic drug
development for two other reasons. First, the diagnosis of pain in both human and
veterinary medicine often relies on measures of pain-depressed behavior (also referred
to as “functional impairment”), and restoration of pain-depressed behavior is often a
goal of treatment (Cleeland and Ryan, 1994; Dworkin et al., 2005). The utility of these
measures in clinical contexts suggests that pain-depressed behaviors may also be
useful as endpoints in research. Second, pain-related depression of behavior is often
accompanied by comorbid depression of mood in humans (Bair et al., 2003; Maletic and
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Raison, 2009), and preclinical research on pain-depressed behavior may provide
insights into the expression, neurobiology and modulation of the affective dimensions of
pain. Thus, assays of pain-depressed behavior would serve as a better tool to evaluate
candidate analgesics in the laboratory animals and would produce better translational
pain research to the clinical field.
Decreases in locomotion, feeding, and positively reinforced operant responding
are common examples of pain-depressed behaviors in laboratory animals. Operant
conditioning provides one strategy for generating high, stable and quantifiable rates of
baseline behavior that can be used to assess effects of putative pain states. Intracranial
self-stimulation (ICSS) in rats is one example of operant responding. In this procedure,
rats are implanted with intracranial electrodes targeting the medial forebrain bundle, and
lever-press responding is maintained under a schedule of brain stimulation. The ability
of brain stimulation to function as a reinforcing stimulus was first discovered in 1954
(Olds and Milner, 1954), and ICSS maintained by stimulation of the medial forebrain
bundle is mediated by activation of excitatory inputs to the mesolimbic dopamine
neurons that originate in VTA. Electrical stimulation to the medial forebrain bundle, and
the subsequent activation of dopaminergic neurons in the mesolimbic pathway,
functions as a highly reinforcing stimulus compared to other reinforcers such as food.
Moreover, it generates a stable behavior that can be efficiently assessed during short
daily behavioral sessions, and it is non-satiable compared to behaviors maintained by
other reinforcers such as food. Also, using ICSS gives the experimenter the ability to
determine the anatomical significance of brain areas in pain and/or analgesia by directly
implanting the electrode into the area(s) of interest in the animal’s brain. In this case,
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the brain of area of interest is the VTA given its potential role in both abuse-related and
analgesic effects of mu agonists. Finally, it has been shown that administration of an
acute noxious stimulus, such as intraperitoneal injection of lactic acid, depresses ICSS,
and this depression can blocked by pretreatment with clinically effective analgesics
such as NSAIDs. Thus, for all these reasons, this project uses ICSS as a behavioral
baseline for research on pain-depressed behavior that will be beneficial to examine the
pharmacology of opioids in the presence and absence of noxious stimulus.

1.3.1

Antinociceptive effects of opioids in assays of pain-stimulated behavior
Pain-stimulated behaviors are widely used in animal research to evaluate drug-

induced antinociception. As one simple example, tail-withdrawal assays of thermal
nociception apply a noxious thermal stimulus (e.g. a hot light or hot water) to the tail of a
rodent or non-human primate and measure the latency to a tail withdrawal response. In
this example, application of the hot stimulus is intended to produce “pain,” and tail
withdrawal is an unconditioned behavioral response interpreted as evidence of “pain”.
The intensity of the noxious stimulus (hot water) is often manipulated by simply
changing the temperature of the hot water. Another example to induce “pain” in animals
is by injecting them with a chemical irritant, such as intraperitoneal injection of dilute
acid. This will produce withdrawal-like stretching/writhing from an inescapable stimulus
(in this case, acid). In both examples, drugs or other treatments can then be evaluated
for their effects on expression of the pain-related behavior.
Opioids have been extensively studied in these and other assays of painstimulated behavior, and opioids consistently produced antinociception in these assays.

- 19 -

For example, pretreatment with morphine produced thermal antinociception in a warmwater tail-withdrawal assay in rats and mice (Morgan et al., 1999; Cook et al., 2000),
and decreased the number of stretches after IP administration of acid in mice and rats
(Barbaz et al., 1988; Pereira Do Carmo et al., 2009). These assays are used also to
determine the role of drug efficacy at the mu opioid receptor. For example, low-efficacy
mu agonists such as nalbuphine and buprenorphine often produce antinociception
against low- but not high-intensity noxious thermal stimuli, whereas higher efficacy mu
agonists such as morphine, fentanyl and methadone are more likely to produce
antinociception against both low- and high-intensity noxious stimuli (Morgan et al., 1999;
Negus and Mello, 1999; Cook et al., 2000). Such data provide one source of evidence
to suggest that antinociception against low-intensity thermal noxious stimuli has lower
efficacy requirements than antinociception against high-intensity thermal noxious
stimuli. Likewise, high- and low-efficacy mu agonists produced a decrease in stretching
response after IP administration of acid (Pchelintsev et al., 1991; Patrick et al., 1999).
However, to the author’s knowledge, the interaction between drug efficacy at the mu
receptor and noxious stimulus intensity has not been investigated previously in assays
of chemically-induced stretching. The author expects that high-efficacy agonists will
retain their antinociceptive effectiveness at high- and low- stimulus intensities, whereas
low-efficacy agonists will lose their antinociceptive effects at the high stimulus intensity.
In addition to these effects of mu opioid efficacy, antinociception in assays of
pain-stimulated behavior is also modified by regimens of prior opioid exposure. For
example, repeated morphine administration produced tolerance to morphine’s
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antinociception effects in both a warm-water tail-withdrawal assay (Walker and Young,
2001) and in an assay of acid-stimulated stretching (Taber et al., 1969).
The goal of this project was to extend this preclinical assessment of opioid
antinociception to an assay of pain-depressed behavior. In particular, experiments in
this project will explore the degree to which mu agonist antinociception in an assay of
pain-depressed ICSS is determined by the efficacy of the mu agonist and by the degree
of prior opioid exposure.

1.4.

Intracranial self-stimulation and opioids
As a complement to assessment of mu agonists’ effects on ICSS in the presence

of pain, we also examined effects of mu agonists on ICSS in the absence of pain. As
mentioned earlier, ICSS comprises a family of operant procedures in which responding
is maintained by electrical stimuli delivered to target brain regions such as the medial
forebrain bundle at the level of the lateral hypothalamus (Olds and Milner, 1954;
Carlezon and Chartoff, 2007). One application of ICSS has been to generate stable
baselines of schedule controlled responding for use in evaluating abuse-related drug
effects (Kornetsky et al., 1979; Wise, 1998). Within this research tradition, facilitation of
ICSS (indicated by increased rates of ICSS) is often interpreted as a rewarding drug
effect that may contribute to, or be predictive of, abuse liability by that drug in humans.
For example, amphetamine is representative of one class of abused drugs (i.e. indirect
dopamine agonists) that reliably and robustly facilitate ICSS across a broad range of
experimental conditions in rats (Esposito et al., 1980; Do Carmo et al., 2009).
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Mu opioid agonists, including morphine, constitute another class of abused drugs
that has been evaluated extensively in ICSS, but mu agonist effects on ICSS have been
less consistent than effects produced by amphetamine-like stimulants. More specifically,
mu agonist effects seem to be influenced by the particular type of procedure used to
assess ICSS performance, and by other factors that include pretreatment time and
extent of prior exposure to opioids. In the simplest type of ICSS procedure, responding
produces electrical stimulation of a constant magnitude, and the primary dependent
measure is the rate of responding or reinforcement. This approach can generate
relatively constant rates of ICSS, and early studies using this approach revealed two
major findings (Adams et al., 1972; Lorens and Mitchell, 1973; Koob et al., 1975). First,
acute treatment with morphine or other mu agonists produced effects with a biphasic
time course consisting of an initial decrease followed by a subsequent increase in rates
of ICSS. Second, repeated or chronic treatment produced tolerance to the initial ratedecreasing effects and earlier expression of rate-increasing effects. As appreciated by
investigators using this constant-reinforcer magnitude approach, expression of ratedecreasing or rate-increasing effects depended in part on baseline ICSS rates
engendered by the selected reinforcer magnitude. High stimulus magnitudes (i.e. high
intensity or frequency) maintained high ICSS rates preferentially sensitive to ratedecreasing effects, whereas lower stimulus magnitudes maintained lower ICSS rates
preferentially sensitive to rate-increasing effects.
More recent studies have evaluated mu agonist’s effects using more
sophisticated ICSS procedures, in which reinforcer magnitude is systematically
manipulated during each experimental session by manipulating either the intensity or
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the frequency of electrical stimulation. Although these procedures have the potential to
efficiently assess drug effects on a wide range of ICSS rates maintained by a wide
range of reinforcer magnitudes, the focus has been on threshold reinforcer magnitudes
that maintain low rates or low probabilities of responding and are especially sensitive to
rate-increasing effects linked to abuse liability. In accordance with this sensitivity, some
studies reported rapid facilitation of ICSS after acute treatment with low mu agonist
doses (Kornetsky and Esposito, 1979; Carlezon and Wise, 1993; Jha et al., 2004),
although this finding has not always been obtained (Stratmann and Craft, 1997; Pereira
Do Carmo et al., 2009). Other studies have provided evidence to suggest that, in
accordance with earlier studies using simpler procedures, facilitation of ICSS may be
more robust later in the time course after acute mu agonist treatment or after chronic
treatment (Craft et al., 2001; O'Neill and Todtenkopf, 2010).
In the current project, the effect of mu opioid agonist on ICSS in the presence
and in the absence of pain had been evaluated using a ‘frequency–rate’ procedure, in
which the frequency of the reinforcing electrical stimulus was varied to generate a wide
range of response rates during each daily session.

1.5.

Introduction to data chapters
The goal of this project was to assess opioid pharmacology in ICSS as an assay

of pain-depressed behavior. As mentioned earlier, ICSS is a sensitive assay to the
abuse-related effects of drugs of abuse, including opioids. Thus, this project evaluated
opioid agonists in two phases:
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1) Phase one: effects of mu opioids in the absence of noxious stimulus. During this
phase, mu opioid agonists were tested in ICSS in conjunction with manipulation of
different independent variables, including pretreatment time, dose, drug efficacy at the
mu receptor, and repeated drug administration. Results of these studies are presented
and discussed in three sections (chapters):
a) Chapter 2: Effects of morphine dose, pretreatment time, repeated
treatment, and rate-dependency on ICSS. Morphine is the prototype
opioid analgesic to which all other opioids are compared. It is the first
opioid to be discovered and isolated from the poppy plant.
b) Chapter 3: Effects of methadone and nalbuphine on ICSS. Methadone is a
high-efficacy mu opioid ligand, while nalbuphine is a low-efficacy ligand at
the mu receptors. The efficacy of these drugs was determined previously
using agonist-stimulated GTP Gamma [S] binding assay (Selley et al.,
1998). Morphine`s efficacy at the mu receptor falls between that of
methadone and nalbuphine.
c) Chapter 4: Effects of high-, moderate-, and low-efficacy mu opioid
agonists on ICSS before, during, and after chronic morphine exposure.
Methadone, fentanyl, and nalbuphine (from high to low efficacy at the mu
receptor) were tested on ICSS before morphine exposure when subjects
were opioid naive, during 3.2 mg/kg/day morphine exposure, and during
18 mg/kg/day morphine exposure. The doses of morphine were selected
to produce different degrees of tolerance and dependence, depending on
results from the previous sections. Tolerance is a term used to describe
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the need for an increasing dose to achieve the same effect; while
dependence describes an altered physiological state caused by repeated
drug exposure such that cessation of drug administration (or after
administration of an antagonist) leads to a withdrawal syndrome (Nestler,
1996). Dependence was evaluated using the mu-opioid receptor
antagonist, naltrexone.
2) Phase 2: effects of mu opioid agonists in assays of acid-stimulated stretching
and acid-induced depression of ICSS. The same drugs used during phase one
were tested again in ICSS as a pretreatment to a noxious stimulus. The
noxious stimulus used in these experiments was intraperitoneal injection of
dilute lactic acid. Lactic acid releases protons that activate C-fibers through the
activation of Transient Receptor Potential Vanilloid 1 (TRPV1) receptors (Julius
and Basbaum, 2001; Tang et al., 2007), as well as acid-sensing ion channels
(Shimada et al., 2004). An assay of acid-stimulated stretching was used as a
comparison to acid-depressed ICSS. Two sections summarize results from this
phase:
a) Chapter 5: effects of mu opioid agonists on acid-stimulated stretching
and acid-depressed ICSS: role of mu agonist efficacy and noxious
stimulus intensity. Methadone, fentanyl, morphine, hydrocodone,
buprenorphine, and nalbuphine (from high to low efficacy at the mu
receptor (Selley et al., 1997; Selley et al., 1998; Thompson et al.,
2004)) were tested in both assays as a pretreatment to 1.8% lactic
acid. Methadone and nalbuphine effects on ICSS were determined
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during noxious stimulus intensity manipulation, and were tested as a
pretreatment to 5.6% lactic acid.
b) Chapter 6: Morphine antinociception during repeated morphine
administration in assays of acid-stimulated stretching and acid-induced
depression of ICSS. A chronic morphine regimen was used to assess
tolerance to the antinociceptive effects of morphine in both assays.
The regimen described in chapter 6 was chosen based on pilot
experiments. The control group received a daily injection of saline.
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CHAPTER TWO
Some determinants of morphine effects on intracranial self-stimulation in rats:
dose, pretreatment time, repeated treatment, and rate dependence
(2011; Behavioural Pharmacology 22(7):663-673)

2.1. Introduction
Mu agonist effects on ICSS have been less consistent than effects produced by
other classes of abused drugs, such as stimulants. One reason behind this
inconsistency may be related to the type of procedure used to assess ICSS
performance. More specifically, the most commonly used procedures to assess opioid’s
effects on ICSS are simple rate procedures and threshold determination procedures.
One disadvantage of using simple rate procedures is that drug effects on ICSS are
highly dependent on baseline rate of responding. Threshold determination procedures
overcome this disadvantage; However, the focus has been on threshold reinforcer
magnitudes that maintain low rates or low probabilities of responding and are especially
sensitive to rate-increasing effects linked to abuse liability. Other factors that determine
opioid effects on ICSS include pretreatment time and history of drug administration.
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The main goal of this study was to further evaluate the role of dose, pretreatment
time, and regimen of repeated treatment as determinants of morphine effects on ICSS
using a ‘frequency–rate’ procedure, in which the frequency of the reinforcing electrical
stimulus was varied to generate a wide range of response rates during each daily
session.

2.2. Methods

2.2.1. Subjects
Ten adult male Sprague–Dawley rats (Harlan, Frederick, Maryland, USA)
weighing 310–350 g at the time of surgery were used. Rats were individually housed
and were maintained on a 12 h light/dark cycle, with lights on from 06:00 to 18:00 h.
Rats had free access to food and water except during testing. Subject maintenance and
research were in compliance with National Institutes of Health guidelines on care and
use of subjects in research, and all subject-use protocols were approved by the Virginia
Commonwealth University Institutional Animal Care and Use Committee.

2.2.2. Assay of intracranial self-stimulation
Intracranial self-stimulation electrode implantation. Rats were anesthetized
with isoflurane gas (2.5–3% in oxygen; Webster Veterinary, Phoenix, Arizona, USA) for
implantation of stainless steel electrodes (Plastics One, Roanoke, Virginia, USA). One
pole (the cathode) of each bipolar electrode was 0.25mm in diameter and covered with
polyamide insulation except at the flattened tip, whereas the other pole (the anode) was

- 28 -

0.125mm in diameter and uninsulated. The cathode was implanted in the left medial
forebrain bundle at the level of the lateral hypothalamus (2.8mm posterior to bregma,
1.7mm lateral from midsaggital suture, and 7.8mm below dura). The anode was
wrapped around one of three skull screws to serve as the ground, and the skull screws
and electrode assembly were secured to the skull with orthodontic resin. The subjects
were allowed to recover for at least 7 days before commencing ICSS training.
Intracranial self-stimulation apparatus. Experiments were conducted in soundattenuating boxes that contained modular acrylic test chambers (29.2 x 30.5 x 24.1 cm)
equipped with a response lever (4.5 cm wide, extended 2.0 cm through the center of
one wall, 3 cm off the floor), stimulus lights (three lights colored red, yellow, and green,
positioned 7.6 cm directly above the response lever), a 2W white house light, and an
ICSS stimulator (Med Associates, St. Albans, Vermont, USA). Electrodes were
connected to the stimulator through bipolar cables and a swivel connector (Model SL2C,
Plastics One). The stimulator was controlled by a computer and software that also
controlled all the programming parameters and data collection (Med Associates).
Behavioral procedure. After initial shaping of lever-press responding, rats were
trained under a continuous reinforcement schedule of brain stimulation using
procedures similar to those described previously (Do Carmo et al., 2009a, 2009b;
Negus et al., 2010). During experimental sessions, each lever press resulted in the
delivery of a 0.5-s train of square wave cathodal pulses (0.1 ms pulse duration), and
stimulation was accompanied by the illumination of the stimulus lights over the lever.
Responses during the 0.5 s stimulation period did not earn additional stimulation. During
initial training sessions lasting 30–60 min, the frequency of stimulation was held
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constant at 158 Hz, and the stimulation intensity for each rat was adjusted gradually to
the lowest value that would sustain a high rate of reinforcement (>30 stimulations/min).
Once this criterion was met, frequency manipulations were introduced. Sessions
involving frequency manipulations consisted of sequential 10-min components. During
each component, a descending series of 10 current frequencies (158–56 Hz in 0.05 log
increments) was presented, with a 60 s trial at each frequency. A frequency trial was
initiated by a 5 s time-out followed by a 5 s ‘priming’ phase, during which subjects
received five noncontingent stimulations with a 0.5 s interval between each stimulation.
This noncontingent stimulation was then followed by a 50 s ‘response’ phase, during
which responding produced electrical stimulation under the continuous reinforcement
schedule. Training continued with presentation of up to three sequential components
per day, and the current intensity was again adjusted at this stage of training until rats
reliably responded for the first three to four frequency trials of all components for at least
three consecutive days. This intensity was then held constant for the remainder of the
study.
Acute-dosing study. Once training was completed, subsequent studies
examined (a) the time course of acute morphine doses and (b) the effects of repeated
morphine doses. Test sessions to examine the time course of acute morphine doses
consisted of multiple 10-min components identical to those described above. Each
session began with three consecutive ‘baseline’ components. The first baseline
component was considered to be an acclimation component, and data from this
component were discarded. Data from the second and third baseline components were
used to calculate baseline parameters of frequency–rate curves for that session (see
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section Data analysis). Morphine (1.0–10.0mg/kg) or its vehicle (saline) was
administered immediately after the third baseline component. Subsequently,
consecutive pairs of test components were initiated 10, 30, 100, and 300min after
morphine or vehicle treatment. Thus, ICSS performance was evaluated 10–30, 30–50,
100–120, and 300–320min after each treatment. Morphine doses were delivered in a
mixed order across rats. Test sessions were typically conducted on Tuesdays and
Fridays and were separated by at least 3 days. Training sessions consisting of three
components were conducted on Mondays, Wednesdays, Thursdays, and occasionally
on Saturdays. In some cases, data from these training sessions were used to assess
ICSS performance 24 h after high doses of morphine. In these cases, data from the
second and third components of the training session were used as the ‘24 h time point’
for data analysis.
Chronic-dosing study. At the conclusion of the acute-dosing study, the effects
of repeated morphine were evaluated. During the first 3 days of this phase of the study,
rats were exposed daily to three consecutive ‘baseline’ components. Data from the first
component each day were discarded, and data for the second and third components of
each day were averaged to generate the baseline frequency–rate curve for comparison
with subsequent chronic morphine effects (see section Data analysis). Immediately after
the third baseline component on the third day, repeated morphine treatments were
initiated for a period of four consecutive weeks. Rats were treated with 3.2 mg/kg/day
morphine during week 1, 5.6 mg/kg/day morphine during week 2, 10mg/kg/day
morphine during week 3, and 18mg/kg/day morphine during week 4. This regimen dose
was used to minimize lethal outcomes after high morphine doses. Morphine doses were
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administered daily as a single bolus injection at 1:30 p.m., and rats were exposed to two
consecutive ICSS test components 30min after each morphine dose. The following day,
23.5 h after each morphine dose (and immediately before the next morphine dose), rats
were exposed to another three consecutive ICSS test components, and data from the
second and third of these components were used for data analysis. Thus, ICSS
performance was evaluated 30min and 23.5 h after each morphine dose. After the last
dose of 18 mg/kg/day morphine, morphine dosing was terminated, and threecomponent test sessions were conducted daily for an additional 3 days. Again, data
from the second and third components of these sessions were used for data analysis to
assess changes in ICSS during the first 3 days of withdrawal. The primary goal of this
study was to quantify the effects of chronic morphine treatment and withdrawal on
ICSS. However, to provide some assessment of potential somatic withdrawal signs, rats
were also weighed daily, cages were inspected for evidence of diarrhea, and subjects
were observed for signs of teeth chattering and wet-dog shakes immediately before
each daily session.

2.2.3. Drugs
Morphine sulfate was provided by the National Institute on Drug Abuse Drug
Supply Program (Bethesda, Maryland, USA). All solutions were prepared in sterile water
for subcutaneous injection.
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2.2.4. Data Analysis
The primary dependent variable in this ICSS procedure was the reinforcement
rate in stimulations/min during each frequency trial. To normalize these data, raw
reinforcement rates from each trial in each rat were converted to percent maximum
control rate (%MCR) for that rat. During the acute-dosing study, the MCR was
determined daily and was defined as the mean of the maximal rates observed in any
frequency trial during the second and third ‘baseline’ components for that day. For the
repeated-dosing study, the MCR was determined before the initiation of repeated
morphine dosing and was defined as the mean of the maximal rates observed during
the second and third ‘baseline’ components over a period of three consecutive days (six
total baseline components). Thus, %MCR values for each trial were calculated as
(Response Rate during a Frequency Trial / MCR) x 100.
For the acute-dosing study, data from each pair of consecutive test components
at each time point after morphine injection were averaged and normalized to the MCR
for that day as discussed above. For the repeated dosing study, data from each pair of
test components 30 min and 23.5 h after injection were averaged and normalized to the
MCR determined before the initiation of the study as discussed above. For statistical
analysis, normalized data were compared by two-way analysis of variance (ANOVA),
with treatment time and ICSS frequency as the two factors. A significant ANOVA was
followed by a Holm–Sidak post-hoc test, and the criterion for significance was set at P
value of less than 0.05.
To provide an additional summary of ICSS performance during the repeateddosing study, the total number of stimulations per component was calculated as the
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sum of stimulations delivered across all 10 frequency trials of each component. Test
data were then normalized to Morphine effects on ICSS baseline data using the
equation % Baseline Stimulations per Component = (Mean Stimulations per Test
Component / Mean Stimulations per Baseline Component) x 100. Data were then
averaged across rats under each experimental condition and compared by one-way
ANOVA. A significant ANOVA was followed by the Dunnett post-hoc test, and the
criterion for significance was set a priori at P value of less than 0.05.
Finally, rate-dependent effects of morphine under selected conditions were
examined by graphing log percent control ICSS rate after morphine treatment as a
function of log control ICSS rate for each stimulation frequency. For the purposes of
rate-dependency analysis, control ICSS rates at each brain stimulation frequency were
defined as the mean number of stimulations obtained at each frequency after vehicle
treatment for the acute studies, and during the baseline sessions before initiation of
chronic morphine in the chronic studies. Percent control reinforcement rates after
morphine were calculated as [(number of stimulations after morphine / number of
control stimulations) x 100] for each stimulation frequency. The analysis was applied to
data collected (a) 30 and 100 min after acute treatment with 3.2, 5.6, and 10 mg/kg
morphine, and (b) 30 min after the seventh daily treatment with chronic 3.2, 5.6, and 10
mg/kg morphine. The resulting rate-dependency plots were subjected to linear
regression analysis using Prism 5 for Macintosh (GraphPad Software Inc., La Jolla,
California, USA). Morphine effects were considered to be significantly rate-dependent if
the 95% confidence limits of the slope did not include ‘0’ and if P value of less than 0.05
for the regression.
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2.3. Results

2.3.1. Effects of acute morphine
For each test session, a ‘baseline’ ICSS frequency–rate curve was determined
before testing to permit the determination of the MCR for that session. During studies of
acute morphine effects, the average MCR was 56.3±13.0 stimulations/trial.
Reinforcement rates for each rat during each frequency trial of a session were then
normalized as the %MCR for that rat in that session, and the average baseline
frequency–rate curves for each test are shown in Figure 2.1 (gray lines, open squares).
Rats generally did not respond at frequencies of 56–79 Hz, and reinforcement rates
increased across a frequency range of 112–158 Hz. Maximum reinforcement rates were
usually observed at the highest stimulation frequencies. There were no statistically
significant differences between baselines on different days (data not shown).
Figure 2.1 also shows the time course of effects produced by vehicle and
morphine (1.0–10 mg/kg), and detailed statistical results are provided in the figure
legend. Vehicle injection had little effect on ICSS frequency–rate curves, producing
significant but only small increases in reinforcement rates at 100 Hz at 10 and 100 min
after treatment. Morphine produced dose-dependent, time-dependent, and frequencydependent changes in ICSS. At earlier time points (10–30 min), the predominant effect
of morphine was a dose-dependent decrease in reinforcement rates maintained by high
frequencies of brain stimulation (112–158 Hz). These rate-decreasing effects peaked at
30 min, and the highest dose of 10 mg/kg morphine nearly eliminated responding at 30
min. In addition to these predominant rate-decreasing effects at 10 and 30min, low
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doses of 1.0 and 3.2 mg/kg morphine also produced significant but small increases in
reinforcement rates at some lower frequencies. After 100 min, the rate-decreasing
effects of morphine had dissipated for all but the highest morphine dose, and doses of
3.2 and 5.6mg/kg morphine produced significant and robust rate-increasing effects at
intermediate frequencies of brain stimulation (71–100Hz), resulting in leftward shifts in
frequency–rate curves relative to baseline. After 300min, none of the morphine doses
produced effects significantly different from baseline.
Overall, these results suggested that morphine produced rate-decreasing effects
with a relatively short duration of action and rate-increasing effects with a longer
duration of action. Data with 10 mg/kg morphine suggested that a period of predominant
rate-increasing effects may have been missed between 100 and 300 min. To evaluate
this possibility, effects of morphine were determined 180 min after administration of 10
mg/kg morphine in a separate group of three rats (Fig. 2.2). These results confirmed
that 10 mg/kg produced a robust facilitation of ICSS at this time point.

2.3.2. Effects of chronic morphine
Figure 2.3 shows effects of chronic morphine on ICSS. Each panel shows the
baseline frequency–rate curve determined before chronic treatment together with the
frequency–rate curves determined 30 min after morphine on the first and seventh day of
treatment with each morphine dose (3.2–18mg/kg/day). Thus, chronic studies evaluated
morphine effects at a time (30 min) when initial acute studies revealed primarily ratedecreasing effects of morphine.
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Before chronic treatment, the MCR was 54.0±14.1 stimulations/trial, and the
baseline frequency–rate curve was similar to that described above. Lower doses of 3.2
and 5.6 mg/kg morphine produced only rate-increasing effects and leftward shifts in
frequency–rate curves relative to baseline on both days 1 and 7 of treatment. In
general, there was little difference in the effects of morphine on days 1 and 7, although
for the initial dose of 3.2 mg/kg morphine, response rates were slightly but significantly
higher at frequencies of 70 and 112 Hz on day 7 as compared with day 1. The higher
two doses of 10 and 18mg/kg morphine produced only rate-decreasing effects on the
first day of treatment, and these rate-decreasing effects were greater for 18 mg/kg than
for 10 mg/kg morphine. However, after 7 days of treatment, these rate-decreasing
effects were no longer apparent, and both doses produced only rate-increasing effects.
To assess the impact of morphine abstinence and spontaneous morphine
withdrawal on ICSS, frequency– rate curves were also determined before each daily
morphine injection (i.e. 23.5 h after the injection on the previous day). This period of
abstinence was associated with a dose-dependent decrease in ICSS. For example,
figure 2.4a shows summary data for ICSS 23.5 h after the last injection of each dose,
and during the 3 days after termination of treatment with the highest dose of 18
mg/kg/day morphine. After 3.2 and 5.6mg/kg morphine, there were slight but nonsignificant decreases in the total number of stimulations delivered. This effect, however,
was significant after 10 and 18 mg/kg daily morphine administration. Figure 2.4b shows
the frequency– rate curve 23.5 h after the last dose of 18 mg/kg morphine. ICSS
recovered completely back to baseline levels within 3 days after termination of
treatment with 18 mg/kg morphine. Rats were also observed for signs of somatic
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withdrawal before daily ICSS sessions and for 3 days after termination of chronic
morphine. Chronic morphine produced a dose-dependent decrease in body weight.
From a mean ± SEM starting weight before chronic treatment of 454.2±15.7 g,
morphine produced mean± SEM body weight losses of 1.6±1.1, 2.3±1.1, 4.4±0.9, and
7.2±1.0% after 3.2, 5.6, 10, and 18mg/kg morphine, respectively. However, this
decrease in body weight could not confidently be attributed to withdrawal as distinct
from a direct morphine effect, and other somatic signs of opioid withdrawal (diarrhea,
teeth chattering, and wetdog shakes) were not observed.

2.3.3. Rate-dependent effects of morphine on intracranial self-stimulation
Figure 2.5 shows the degree to which morphine effects on ICSS varied as a
function of baseline ICSS rates. Data are shown for results obtained 30min after acute
or chronic treatment with 3.2, 5.6, and 10mg/kg morphine to illustrate the breadth of
changes in rate dependency. Table 2.1 shows results of linear regression analysis
applied to the rate-dependency plots shown in Figure 5, and also shows data obtained
100 min after acute administration of each dose. Overall, the extent of rate dependency
was influenced by dose, pretreatment time, and chronicity of treatment. Effects of the
lowest dose of 3.2mg/kg were not rate-dependent 30 or 100min after acute
administration, but effects were rate-dependent 30min after the last dose of chronic
treatment. Effects of the intermediate dose of 5.6mg/kg morphine were not ratedependent 30min after acute treatment, but became rate-dependent 100min after acute
treatment and 30min after the last dose of chronic treatment. Effects of the high dose of
10 mg/kg morphine were rate-dependent under all conditions; however, the nature of
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that rate dependency changed. Thus, acute 10 mg/kg morphine had little or no effect on
low baseline rates of ICSS but decreased high baseline rates of ICSS. Conversely, after
chronic administration, morphine increased low baseline rates of ICSS but had little
effect on high baseline rates. Overall, morphine exposure produced either by the longer
100min pretreatment time or by chronic treatment had the general effect of increasing
the negative slope, correlation coefficient, and statistical significance of ratedependency plots and shifting these plots vertically upward. After chronic treatment, all
morphine doses produced significant rate-dependent effects expressed as an increase
in low baseline rates of ICSS and little change in high baseline rates of ICSS.

2.3.4. Summary
This study examined morphine effects on ICSS in rats using a ‘frequency–rate’
procedure, in which a wide range of ICSS rates was maintained by a wide range of
brain stimulation frequencies during each daily session. There were three main findings.
First, acute morphine produced time-dependent changes in ICSS such that ratedecreasing effects predominated at earlier time points (10–30 min) whereas rateincreasing effects predominated at later time points (100–180 min). Second, repeated
morphine produced tolerance to rate-decreasing effects and unmasked robust rateincreasing and rate-dependent effects 30 min after morphine administration. Finally,
withdrawal from repeated morphine produced small but significant decreases in ICSS
that recovered over the course of 3 days after withdrawal from the highest morphine
dose. Taken together, these data indicate that morphine dose and pretreatment time,
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the history of morphine exposure, and baseline ICSS rate are critical determinants of
both the magnitude and the valence of morphine effects on ICSS.

- 40 -

Figure 2.1
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Figure 2.1. Morphine pretreatment produced dose-dependent, time-dependent,
and

frequency-dependent

changes

in intracranial

self-stimulation

(ICSS).

Horizontal axes: frequency of electrical brain stimulation in hertz (log scale). Vertical
axes: ICSS rate expressed as percent maximum control rate (%MCR). (a–e) shows
ICSS frequency–rate curves determined before (baseline) or at various times after (10–
300 min) treatment with vehicle (Veh) or morphine (1.0–10 mg/kg). Filled symbols
indicate frequencies at which ICSS rates were significantly lower or higher than baseline
as determined by the Holm–Sidak post-hoc test following a significant analysis of
variance (ANOVA) (P<0.05). ANOVA results were as follows: Vehicle: significant main
effect of frequency [F(9,45)=44.0; P<0.001], significant main effect of time [F(4,20)=3.5;
P=0.025], no significant frequency x time interaction [F(36,180) =1.4; NS]; 1 mg/kg
morphine: significant main effect of frequency [F(9,45)=148.0; P<0.001], no significant
main effect of time [F(4,20)=1.6; NS], significant frequency x time interaction [F(36,180)
=3.0; P<0.001]; 3.2 mg/kg morphine: significant main effect of frequency [F(9,45)=98.7;
P<0.001], significant main effect of time [F(4,20)=3.9; P<0.02], significant frequency x
time interaction [F(36,180) =2.5; P<0.001]; 5.6 mg/kg morphine: significant main effect
of frequency [F(9,45)=88.1; P<0.001], significant main effect of time [F(4,20)=4.2;
P<0.02], significant frequency x time interaction [F(36,180) =4.0; P<0.001]; 10 mg/kg:
significant main effect of frequency [F(9,45)=45.4; P<0.001], significant main effect of
time [F(4,20)=4.0; P<0.02], significant frequency x time interaction [F(36,180) =9.0;
P<0.001]. All points show mean data for six rats, and error bars are omitted for clarity.
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Figure 2.2

Figure 2.2. 10 mg/kg Morphine facilitated intracranial self-stimulation (ICSS) after
180 min. Horizontal axis: frequency of electrical brain stimulation in hertz (log scale).
Vertical axis: ICSS rate expressed as percent maximum control rate (%MCR). Filled
symbols indicate frequencies at which ICSS rates were significantly higher than
baseline as determined by the Holm–Sidak post-hoc test following a significant analysis
of variance (ANOVA) (P<0.05). ANOVA revealed a significant main effect of frequency
[F(9,18)=17.3; P<0.001], no significant effect of treatment [F(1,2)=9.9; P=0.09], but a
significant frequency x treatment interaction [F(9,18)=4.0; P<0.01]. All points show
mean data for three rats.
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Figure 2.3
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Figure 2.3. Effects of chronic morphine on intracranial self-stimulation (ICSS).
Horizontal axes: frequency of electrical brain stimulation in hertz (log scale). Vertical
axes: ICSS rate expressed as percent maximum control rate (%MCR). Rats were
treated for 28 consecutive days with an ascending sequence of four morphine doses
(3.2, 5.6, 10, and 18 mg/kg/day). Each dose was administered for 7 days, and ICSS
frequency–rate curves were determined 30 min after each injection. (a–d) shows
frequency–rate data obtained before chronic morphine (baseline) and on the first and
seventh days of treatment with each morphine dose. Filled symbols indicate frequencies
at which ICSS rates were significantly lower or higher than baseline, and asterisks
indicate frequencies at which ICSS rates on day 7 were significantly higher than rates
on day 1, as determined by the Holm–Sidak post-hoc test following a significant
analysis of variance (ANOVA) (P<0.05). ANOVA results were as follows: 3.2 morphine:
significant main effect of frequency [F(9,36)=28.2; P<0.001], significant main effect of
day [F(2,8)=5.3; P<0.05], significant frequency x day interaction [F(18,72)=4.4;
P<0.001]; 5.6 morphine: significant main effect of frequency [F(9,36) =18.5; P<0.001],
significant main affect of day [F(2,8)=4.5; P<0.05], significant frequency x day
interaction [F(18,72)=4.5; P<0.001]; 10 morphine: significant main effect of frequency
[F(9,36) =25.2; P<0.001], no significant main affect of day [F(2,8)=3.0; NS], and a
significant frequency x day interaction [F(18,72)=3.2; P<0.001]; 18 morphine: significant
main effect of frequency [F(9,36) =27.6; P<0.001], no significant main affect of day
[F(2,8)=2.2; NS], and a significant frequency x day interaction [F(18,72)=5.9; P<0.001].
All points show mean data for five rats.
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Figure 2.4
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Figure 2.4. Effects of morphine abstinence on intracranial self-stimulation (ICSS).
(a) shows the total number of stimulations per component expressed as a percentage of
baseline stimulations per component 23.5 h after the last injection of each dose and
during the 3 days after the last dose of 18 mg/kg morphine. Horizontal axis: dose of
morphine (mg/kg) before abstinence. Vertical axis: percent baseline number of
stimulations per component. One-way analysis of variance (ANOVA) indicated a
significant main effect of abstinence condition [F(6,24)=3.13; P<0.025]. Asterisks
indicate conditions under which total number of stimulations was significantly lower than
baseline (100%), as determined by the Dunnett post-hoc test. (b) shows the baseline
frequency–rate curve and the frequency–rate curve determined on the day after the last
dose of 18 mg/kg morphine. Horizontal axis: frequency of brain stimulation in hertz (log
scale). Vertical axis: ICSS rate expressed as percent maximum control response rate
(%MCR). Two-way ANOVA indicated a significant main effect of frequency [F(9,36)
=57.1; P<0.001], significant main effect of day [F(1,4)=8.3; P<0.05], but no significant
frequency x day interaction [F(9,36) =1.3; NS]. Filled symbols indicate frequencies at
which reinforcement rates were significantly lower than baseline as determined by the
Holm–Sidak post-hoc test. All bars and symbols show mean data from five rats, and
error bars in the right panel show SEM
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Figure 2.5

Figure 2.5. Rate dependency of morphine effects on intracranial self-stimulation
(ICSS). Horizontal axes: Log control ICSS rate (in units of stimulations/ frequency trial)
at each of the 10 frequencies of brain stimulation. Vertical axes: log percent control
ICSS rate observed 30 min after morphine treatment. (a–c) show effects of 3.2, 5.6, and
10 mg/kg morphine during the acute-dosing phase of the study, and after the seventh
daily dose during the chronic dosing phase of the study. All points show mean data for
five to six rats.
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Table 2.1. Linear regression analysis applied to the rate-dependency plots shown in
Fig. 5 and to data obtained 100 min after acute administration of each dose
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CHAPTER THREE
Role of mu-agonist efficacy as determinants of the effects of the mu agonists on
intracranial self-stimulation in rats
(2012; Behavioural Pharmacology 23(7):678-92)

3.1. Introduction
One possible explanation of my findings in chapter two is that mu agonistinduced facilitation of ICSS requires lower levels of receptor occupation and activation
(i.e. has lower efficacy requirements and higher receptor reserve) than mu agonistinduced depression of ICSS. According to this hypothesis, lower morphine doses would
produce sufficient receptor occupancy and activation to facilitate ICSS, whereas higher
doses would produce higher levels of receptor occupancy sufficient to recruit opposing
rate-decreasing effects. Repeated morphine could selectively attenuate rate-decreasing
effects and enhance expression of rate-increasing effects by desensitizing and/or
downregulating some fraction of mu receptors to reduce the functional receptor density
and attenuate the ability of morphine to produce rate-decreasing effects dependent on
high levels of receptor occupancy (Martini and Whistler, 2007). The present study tested
this hypothesis by testing the effect of a high- and a low- efficacy agonists on ICSS. The
hypothesis predicted that higher-efficacy mu agonists would have sufficient efficacy to
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produce both morphine-like rate-increasing and rate-decreasing effects, but that lower
efficacy mu agonists might lack sufficient efficacy to produce rate-decreasing effects
and might therefore produce enhanced rate-increasing effects.

3.2. Methods

3.2.1. Subjects
Subjects are similar to those described on section 2.2.1. The total number of
subjects in this study was 17.

3.2.2. Assay of intracranial self-stimulation
Intracranial self-stimulation electrode implantation and behavioral procedure are
similar to those described on section 2.2.2.
Effects of opioid agonists with varying efficacies at the mu receptor. Three
groups of rats were used in this experiment. In the first group, the high efficacy agonist
methadone (0.032–5.6 mg/kg), the low efficacy against nalbuphine (0.032–10 mg/kg),
naltrexone (0.1 mg/kg), and vehicle (saline) were tested (n=5). Morphine was tested
first, and the results were similar to those reported previously (Altarifi and Negus, 2011),
and are not discussed further. For each drug, except naltrexone, testing was conducted
in two phases. During the first phase, the dose was manipulated from doses that
produced no effect on ICSS to doses that either (a) significantly decreased ICSS or (b)
were at least 10 times greater than the lowest dose to significantly facilitate ICSS. Test
sessions consisted of three consecutive control components, followed immediately by
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injection of the drug and then 30 min later by two consecutive test components. During
the second phase, the time course of the dose producing peak facilitation of ICSS was
determined. Test sessions consisted of three consecutive control components, followed
immediately by injection of the drug and then by consecutive pairs of test components
that began 10, 30, 100, 180, and 300 min after injection. Naltrexone was tested at a
single dose (0.1 mg/kg) alone and as a 20-min pretreatment to 1.0 mg/kg methadone.
One rat died before studies with naltrexone; thus, these studies were carried out with
only four rats. The remaining two groups were used in experiments to examine the
effects of the highest efficacy mu agonist methadone (0.032–3.2 mg/kg) and the lowest
efficacy mu agonist nalbuphine (0.032–10 mg/kg) in separate groups of opioid-naive
rats.
In all experiments, sessions were typically conducted on Tuesdays and Fridays
and were separated by at least 3 days. This intermittent-dosing regimen was intended
to minimize the development of tolerance to drug effects on ICSS. Training sessions
consisting of three components were conducted on Mondays, Wednesdays, Thursdays,
and occasionally, on Saturdays. In some cases, data from these training sessions were
used to assess ICSS performance 24 h after injection in the time-course studies. In
these cases, data from the second and the third components of the training session
were used as the ‘24-h time point’ for data analysis.

3.2.3. Drugs
Methadone HCl and naltrexone HCl were provided by the National Institute on
Drug Abuse Drug Supply Program (Bethesda, Maryland, USA). Nalbuphine HCl was
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provided by Dr Kenner Rice (Chemical Biology Branch, National Institute on Drug
Abuse and National Institute on Alcohol Abuse and Alcoholism, Bethesda, Maryland,
USA). All drugs were dissolved in saline and delivered subcutaneously in a volume of
1ml/kg body weight.

3.2.4. Data analysis
The primary dependent variable was the reinforcement rate in stimulations/trial
during each frequency trial. To normalize these raw data, reinforcement rates from each
trial were converted into the percent maximum control rate (%MCR) for that rat on that
day. The MCR was determined during the control components of each test session and
was defined as the mean of the maximal rates observed in any frequency trial during
the second and third control components. Thus, %MCR for each trial was calculated as
(reinforcement rate during a frequency trial / MCR) x 100. Normalized data from the
frequency trials of each pair of consecutive test components were then averaged across
rats for display and for statistical analysis using two-way analysis of variance (ANOVA),
with drug dose or time as one factor and ICSS frequency as the other factor. A
significant ANOVA was followed by a Holm–Sidak post-hoc test, and the criterion for
significance was set at P less than 0.05.
To provide an additional summary of ICSS performance, the total number of
stimulations per component was calculated as the average of the total stimulations
delivered across all 10 frequency trials of each component. Test data were expressed
as a percentage of the total stimulations earned during the ‘control’ components (%
control stimulations). Thus, % control stimulations for each test were calculated as

- 53 -

(mean total stimulations during test components / mean total stimulations during control
components) x 100.

3.3. Results
The control parameters of ICSS did not vary significantly during sequential
testing with mu-opioid receptor ligands in a group of five rats, and the overall mean
control parameters of all three groups are shown in Table 3.1. In the first group (i.e. has
history of opioid administration), the high efficacy mu agonist methadone exerted dosedependent effects on ICSS, manifested as the exclusive facilitation of ICSS at relatively
low to intermediate doses (0.32 - 1.0 mg/kg) and emergence of rate-decreasing effects
at high doses (3.2 – 5.6 mg/kg; Fig. 3.1). The lower efficacy mu agonist nalbuphine also
produced exclusive facilitation of ICSS at relatively low doses; however, in contrast to
the higher efficacy mu agonist methadone, nalbuphine continued to produce exclusive
facilitation of ICSS at doses up to 30-fold higher than the lowest doses to produce
facilitation (Fig. 3.1). The opioid antagonist naltrexone did not alter ICSS at a dose
sufficient to antagonize methadone-induced facilitation of ICSS (Fig. 3.1). Both drugs
had the same potency to facilitate ICSS and figure 3.2 shows that both drugs produced
peak facilitation of ICSS at the earliest time tested (10 min), and the speed of offset was
faster for nalbuphine than methadone (100 vs. 180 min, respectively). Treatment with
vehicle (saline) did not produce significant changes in
ICSS at any time point.
Figure 3.3 shows the effects of methadone and nalbuphine in two separate
groups of opioid-naive rats. Relative to their effects in the initial group of opioid-

- 54 -

experienced rats shown in Figure 3.1, methadone and nalbuphine produced weaker
ICSS facilitation, and methadone produced more potent ICSS depression. For example,
1.0mg/kg methadone facilitated low rates of ICSS maintained by low frequencies of
brain stimulation in opioid-experienced rats (Fig. 3.1), but only depressed high rates of
ICSS maintained by high frequencies of brain stimulation in opioid-naive rats (Fig. 3.3).
Similarly, nalbuphine produced greater magnitudes of ICSS facilitation across a broader
range of frequencies in opioid-experienced rats (Fig. 3.1) than in opioid-naive rats
(facilitation only at 89Hz after 0.32 and 10 mg/kg; Fig. 3.3). Notably, nalbuphine did not
significantly decrease ICSS at any dose in opioid-naive rats, but this absence of ratedecreasing effects was not associated with enhanced expression of rate-increasing
effects relative to methadone.

3.4. Summary
Mu opioid receptor agonists such as morphine can either facilitate or depress
ICSS, and previous opioid exposure can increase the expression of abuse-related ICSS
facilitation (Chapter 2). This study tested the hypothesis that rate-decreasing effects
require higher activation of mu receptors, and hence are more vulnerable to toleranceassociated reductions in receptor density, than rate-increasing effects. I tested a high
efficacy mu agonist (methadone) as well as a low efficacy mu agonist (nalbuphine).
Each drug was tested twice in two separate groups of subjects: the first group was
opioid experienced, and the other group was naïve. The hypothesis predicted that
nalbuphine, would mimic the effects of morphine tolerance to produce the reduced
expression of rate-decreasing effects and enhanced expression of rate-increasing
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effects, while methadone would mimic the effects of morphine during acute
administration. In contrast to this hypothesis, in opioid-naïve rats, a reduction in the
efficacy of mu agonists was associated with a decreased expression of rate-decreasing
effects, but not a tolerance-like enhancement in ICSS facilitation. These results suggest
that history of opioid exposure influences effects of mu opioid receptor agonists on
ICSS, and that mu agonist-induced facilitation and depression of ICSS may be
mediated by distinct populations of mu receptors that respond differently to regimens of
opioid exposure.
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Figure 3.1.
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Figure 3.1. Effects of methadone (a, b), nalbuphine (c, d), or “naltrexone +
methadone” (e, f) on ICSS in opioid-experienced rats. The left column (panels a, c,
and e) shows the ICSS frequency–rate curves. Horizontal axes: frequency of electrical
brain stimulation in Hz (log scale). Vertical axes: ICSS rate expressed as percent
maximum control rate (%MCR). Data obtained for some doses were excluded from the
graph for clarity, but were included in statistical analyses. Filled symbols indicate the
frequencies at which morphine ICSS rates were greater than those obtained during
control components, as determined by the Holm–Sidak post-hoc test following a
significant two-way ANOVA. The right column (panels b, d, and f) shows the total
number of stimulations per test component, expressed as a percentage of the total
control stimulations. Horizontal axes: dose. Vertical axes: percent control stimulations
per test component. Upward and downward arrows indicate the presence and valence
of the effects of test drug as determined by analyses of frequency–rate data. Thus,
upward arrows indicate significant facilitation of ICSS at ≥1 frequency of the frequency–
rate curve, whereas downward arrows indicate significant depression of ICSS at ≥1
frequency of the frequency–rate curve. ANOVA results were as follows: methadone:
significant main effect of frequency [F(9,36) =71.2; P<0.001], significant main effect of
dose [F(5,20)=3.8; P=0.014], and significant dose x frequency interaction
[F(45,180)=3.8; P<0.001]; nalbuphine: significant main effect of frequency [F(9,36)
=27.1; P<0.001], significant main effect of dose [F(5,20)=10.8; P<0.001], and significant
dose x frequency interaction [F(45,180)=1.8; P=0.005]; naltrexone: significant main
effect of frequency [F(9,27)=27.4; P<0.001], significant main effect of treatment
[F(3,9)=7.1; P=0.009], and significant treatment x frequency interaction [F(27,81)=3.5;
P<0.001]. ANOVA, analysis of variance; ICSS, intracranial self-stimulation; MCR,
maximum control rate; NTX, naltrexone; Veh, vehicle
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Figure 3.2.

Figure 3.2. Time courses of mu-opioid receptor agonist effects on ICSS. Time
course of the dose producing peak facilitation of ICSS for each drug as shown in Figs
3.1 was determined. Horizontal axes: time elapsed after the injection of the test drug.
Vertical axes: percent control stimulations per test component. ANOVA results were as
follows: methadone: significant main effect of frequency [F(9,36) =92.8; P<0.001],
significant main effect of time [F(6,24)=15.1; P<0.001], and significant time x frequency
interaction [F(45,216)=2.2; P<0.001]; nalbuphine: significant main effect of frequency
[F(9,27)=36.5; P<0.001], significant main effect of time [F(5,15)=7.8; P<0.001], and no
significant time x frequency interaction [F(45,135)=1.2; P=0.181]; vehicle: significant
main effect of frequency [F(9,27)=36.7; P<0.001], no significant main effect of time
[F(6,18)=1.6; P=0.215], and no significant time x frequency interaction [F(54,162)=1.2;
P=0.250]. For a description of symbols, please refer to Fig. 1. ANOVA, analysis of
variance; ICSS, intracranial self-stimulation.
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Figure 3.3

Figure 3.3. Effects of the high-efficacy m agonist methadone (a, b) and the lowefficacy nalbuphine (c, d) on ICSS in separate groups of opioid-naive rats. ANOVA
results were as follows: methadone: significant main effect of frequency [F(9,45)=33.8;
P<0.001], significant main effect of dose [F(5,25)=18.5; P<0.001], and significant dose x
frequency interaction [F(45,225)=8.2; P<0.001]; nalbuphine: significant main effect of
frequency [F(9,45)=30.0; P<0.001], no significant main effect of dose [F(6,30)=2.2;
P=0.074], and significant dose x frequency interaction [F(54,270)=2.2; P<0.001]. For a
description of axes and symbols, please refer to Fig. 3.1. ANOVA, analysis of variance;
ICSS, intracranial self-stimulation; MCR, maximum control rate; Veh, vehicle.
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Table 3.1. Control MCR and Total Stimulations obtained during experiments to
determine the effects of mu-opioid receptor ligands.

MCR ± SE

Total Stimulations ± SE

Mu ligands (Opioid experienced)

54.8 ± 12.6

291.7 ± 82.6

Methadone (naïve)

57.1 ± 6.1

221.5 ± 48.4

Nalbuphine (naïve)

57.3 ± 10.6

207.8 ± 91.6
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CHAPTER FOUR
Abuse-related effects of mu opioid analgesics in an assay of intracranial selfstimulation in rats: modulation by chronic morphine exposure
(Behavioural Pharmacology; submitted)

4.1. Introduction
The purpose of the present study was to extend my previous research on
determinants of mu opioid agonists on ICSS in rats (Altarifi and Negus, 2011; Altarifi et
al., 2012). Specifically, my previous studies identified two general phenomena. First,
effects of mu agonists on ICSS in subjects with no prior history of opioid exposure were
dependent on the efficacy of the opioid at mu receptors (with in vitro efficacy to
stimulate GTPγS binding as the metric of efficacy; Selley et al., 1998). High- to
intermediate-efficacy mu agonists such as methadone and morphine produced biphasic
effects that included both increases in low ICSS rates maintained by low brain
stimulation frequencies and decreases in high ICSS rates maintained by high brain
stimulation frequencies. Conversely, lower efficacy mu agonists such as nalbuphine
were less effective to produce both rate-increasing and rate-decreasing effects, and the
opioid antagonist naltrexone did not alter ICSS at doses that blocked the effects of mu
agonists (Chapter 3). Second, with morphine, chronic treatment produced tolerance to
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rate-decreasing effects and enhanced expression of rate-increasing effects, and
prevailing evidence suggests that this differential tolerance reflects greater
desensitization by chronic morphine of mu receptors mediating rate-decreasing than
rate-increasing effects (Altarifi et al., 2012; Miller et al., submitted).
The present study examined the interaction between these two phenomena by
evaluating effects of chronic morphine exposure on changes in ICSS produced by four
mu opioid receptor ligands that vary in efficacy at mu receptors: the high-efficacy mu
agonist methadone, the intermediate efficacy mu agonist fentanyl, the low-efficacy mu
agonist nalbuphine, and the mu antagonist naltrexone (Selley et al., 1998). I
hypothesized that chronic morphine would produce the following efficacy-dependent
effects: (1) tolerance to rate-decreasing effects for all agonists, with the potential for
greater tolerance to lower efficacy agonists; (2) lesser or no tolerance to rate-increasing
effects for all agonists, with the potential for greater tolerance to the lower efficacy
agonists; and (3) dependence as indicated by the emergence of withdrawal-associated
depression of ICSS by naltrexone and possibly also by nalbuphine.

4.2. Methods

4.2.1. Subjects
Subjects are similar to those described on section 2.2.1.
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4.2.2. Assay of intracranial self-stimulation
Intracranial self-stimulation electrode implantation and behavioral procedure are
similar to those described on section 2.2.2.
Testing: Once training and habituation to saline injections were completed, “predrug baseline” sessions were conducted over a period of 3 consecutive days to
establish baseline ICSS performance before administration of any mu agonists. Each
pre-drug baseline session consisted of 3 components as described in section 2.2.2.
Rats were then distributed into 3 different groups. Each group received a different test
drug (methadone 0.32-5.6 mg/kg; fentanyl 0.003-0.1 mg/kg; or nalbuphine 0.1-10
mg/kg). Testing in each group proceeded in three phases to evaluate test drug effects
before chronic morphine (phase 1), during daily treatment with 3.2 mg/kg/day morphine
(phase 2) and during treatment with 18 mg/kg/day morphine (phase 3). In addition to
being tested with their designated test mu agonist during each phase, all rats were also
tested with 0.1 mg/kg naltrexone after mu agonist testing during phase 3. Rats in the
methadone and nalbuphine groups were also tested again 3 weeks after termination of
repeated morphine (phase 4). Table 4.1 summarizes the sequence of treatments in all
groups.
The first phase started immediately after the third pre-drug baseline session and
lasted for 15-20 days. Daily ICSS sessions in this and all subsequent phases consisted
of (a) three consecutive daily-baseline components, (b) a 30 min time out, with
administration of saline or drug at the beginning of the time out, and (c) two more test
components. Thus, ICSS was assessed twice each day: once during the daily-baseline
components before that day’s injection of saline or drug (and approximately 23 hr after
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the previous day’s injection), and once during the test components that began 30 min
after that day’s injection. After the last component, subjects were removed from the test
chamber and returned to their home cages. Test sessions involving administration of
active doses of the test drug were separated by at least three days in the fentanyl
group, which was the first group studied. A modification in experimental design was
introduced for the later methadone and nalbuphine groups (see below for rationale), and
in these groups, test sessions with active doses were separated by at least two days.
For all groups, saline was administered instead of test drug on intervening days. ICSS
sessions were sometimes omitted on weekends.
The second phase started with a 7-day maintenance period, during which 3.2
mg/kg/day morphine was administered during the time out of each daily ICSS session.
On day 8, test sessions were resumed, and test drug effects were redetermined using
the same dose order and intervals as the first phase. In addition, the fentanyl group
was also tested with an additional higher dose in phase two after testing with the
original doses was completed. On days that subjects did not receive test drug, they
received 3.2 mg/kg morphine. This morphine injection was usually administered during
the time out of an ICSS session as described above; however, ICSS sessions were
occasionally omitted during the weekends, and on these days, the morphine injection
was administered without ICSS. As in phase 1, test sessions for fentanyl were
separated by at least three days, so that each test session was preceded by at least two
days of treatment with the chronic morphine dose. In the methadone and nalbuphine
groups, an alternative design was implemented to minimize protracted opioid withdrawal
on days when saline or low test-drug doses were examined. Thus, when subjects were
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tested with saline vehicle or with low doses of methadone (0.32 mg/kg) or nalbuphine
(0.1-0.32 mg/kg), they also received a supplemental dose of 3.2 mg/kg morphine after
the final component on that day, before returning to their home cages. Supplemental
doses were not administered after higher doses of methadone or nalbuphine to
minimize the potential for opioid overdose. Phase two lasted 20-25 days.
The third phase began with a gradual increase in the morphine dose
administered during the time out of consecutive daily ICSS sessions. Typically, subjects
received 5.6 mg/kg/day morphine for 2 days, followed by 10 mg/kg/day morphine for 2-4
days, followed by the terminal dose of 18 mg/kg/day for the remainder of the third
phase. The rate of dose escalation was individually determined in each rat to assure
expression of ICSS at a given dose before proceeding to a higher dose. Once the
terminal dose of 18 mg/kg/day morphine was achieved, it was maintained for seven
days. Subsequently, test sessions were resumed, and test drug effects were
redetermined using the same dose order and intervals as in the second phase. In
addition, the methadone group was also tested with an additional higher dose in phase
3 after testing with the original doses was completed. Also, all subjects were tested with
0.1 mg/kg naltrexone (NLTX) after testing with the designated mu agonist was
completed. This naltrexone dose was selected as a dose that did not alter ICSS in nondependent rats but that blocked methadone-induced facilitation of ICSS in a previous
study (Altarifi et al., 2012). Subjects in this phase received 18 mg/kg/day morphine on
the days that they did not receive test drug, and 18 mg/kg morphine was also
administered at the end of test sessions during which saline vehicle or low methadone
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(0.32-1.0 mg/kg), or nalbuphine (0.1-3.2 mg/kg) doses were tested. Phase three lasted
between 20-25 days.
At the end of the third phase, daily morphine injections were terminated, but daily
ICSS sessions continued for at least three days. No further experiments were
conducted in the fentanyl group. For the methadone and nalbuphine groups, ICSS
sessions and drug treatments were suspended for two weeks. Training was then
resumed for three days, after which an extra phase (phase four) was conducted in these
subjects identical to phase 1.

4.2.3. Drugs
Morphine sulfate, methadone HCl, naltrexone HCl and fentanyl HCl were
provided by the National Institute on Drug Abuse Drug Supply Program (Bethesda, MD).
Nalbuphine HCl was provided by Dr. Kenner Rice (Chemical Biology Branch, National
Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism,
Bethesda, MD). All drugs were dissolved in saline and delivered subcutaneously in a
volume of 1 ml/kg body weight.

4.2.4. Data Analysis
The primary dependent variable was the reinforcement rate in stimulations/trial
during each frequency trial. To normalize these raw data, reinforcement rates from each
trial in each rat were converted to Percent Maximum Control Rate (%MCR) for that rat.
The maximum control rate was determined for each rat during the pre-drug baseline
sessions at the beginning of the experiment. The first component from these sessions
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(and from all other sessions) was considered to be an acclimation component, and data
were discarded. The maximum control rate was defined as the mean of the maximal
rates observed during any frequency trial of the second and third components of the
three pre-drug baseline sessions (six total pre-drug baseline components).
Subsequently, %MCR for each trial was calculated as (Reinforcement Rate During a
Frequency Trial ÷ Maximum Control Rate) × 100. Graphs show mean frequency-rate
curves, with brain stimulation frequency on the abscissa, and ICSS rate expressed as
%MCR on the ordinate.
Frequency-rate curves from test sessions during each phase of the study were
submitted for analysis. As noted above, these frequency-rate curves were assessed
twice on each test day: once during daily baseline components before that day’s
injection (and approximately 23 hr after the previous day’s injection), and again during
test components that began 30 min after that day’s injection. Daily baseline data and
test data from test sessions were analyzed separately. The daily baseline data
provided information on changes in baseline ICSS produced by the chronic treatment
(saline, 3.2 mg/kg/day morphine, or 18 mg/kg/day morphine). More specifically,
because daily baseline components were conducted approximately 23 hr after the most
recent injection of the chronic treatment, they provided data on changes in ICSS
produced by 23 hr withdrawal from that treatment. Because rats in all three test drug
groups received the same progression of chronic morphine treatments during sequential
phases of the study, daily baseline data from test sessions within each phase were
averaged across all rats to yield mean baseline ICSS data during chronic treatment with
saline, 3.2 mg/kg/day morphine and 18/mg/kg/day morphine. These mean baseline
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data during each phase were compared to the pre-drug baseline data using two-way
ANOVA, with phase of chronic treatment as one factor and ICSS frequency as the other
factor. A significant ANOVA was followed by a Holm-Sidak post hoc test, and the
criterion for significance was set at p < 0.05. To facilitate within-subject data analysis,
data were included only for those rats that completed all three phases of chronic
morphine treatment (N=15, 5 from each group).
Test data from each test session were analyzed to assess dose effects of each
test drug (methadone, fentanyl, nalbuphine) on ICSS frequency-rate curves during each
phase of chronic morphine treatment. Within each phase, ICSS test data for a given
dose were averaged across rats and compared by two-way ANOVA, with drug dose as
one factor and ICSS frequency as the other factor. A similar approach was used to
compare effects of saline and 0.1 mg/kg naltrexone treatment during phase 3. A
significant ANOVA was followed by a Holm-Sidak post hoc test, and the criterion for
significance was set at p < 0.05. Data were included for all rats that completed a given
phase.
To provide an additional summary measure of baseline and test ICSS
performance, the total number of stimulations per component was calculated as the
average of the total stimulations delivered across all 10 frequency trials of each
component. Baseline and test data were expressed as a percentage of the total
stimulations per component earned during the “pre-drug baseline” components (%
Control). Thus, % Control was calculated as (Mean Total Stimulations During Daily
Baseline or Test Components ÷ Mean Total Stimulations During Pre-Drug Baseline
Components) × 100.
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4.3. Results
Baseline ICSS before and during chronic morphine. During pre-drug
baseline sessions, the average maximum control rate (MCR) for all rats in the study was
57.2 ± 9.8 stimulations per trial, and the average control number of total stimulations
delivered across all frequencies was 286.7±70.7. Table 4.2 shows the MCR and control
number of total stimulations for each group of rats. Figure 4.1 shows mean frequencyrate ICSS curves before treatment and during phases 1-3 of chronic morphine
treatment. During baseline (i.e. before any drug administration), little responding was
maintained by the lower frequencies of stimulation (56-79 Hz), and ICSS increased at
the intermediate and higher frequencies (89-158 Hz). Chronic treatment with vehicle
(phase 1) and 3.2 mg/kg morphine (phase 2) did not significantly alter ICSS. During
phase 3, treatment with repeated 18 mg/kg/day morphine produced a decrease in ICSS
relative to the pre-drug baseline (significant at 100-126 Hz). ICSS partially recovered
within three days after termination of chronic morphine, although ICSS rates were still
significantly depressed at one frequency (112 Hz).
Effects of methadone on ICSS before and during chronic morphine. Figure
4.2 shows the effect of methadone on ICSS during phases 1-3. During phase 1,
methadone failed to facilitate ICSS at any brain stimulation frequency. Rather,
methadone dose-dependently decreased ICSS maintained by high frequencies of brain
stimulation, with significant depression at 126-158 Hz after 1.0 mg/kg methadone and at
100-158 Hz after 3.2 mg/kg methadone (figure 4.2 a,b). Repeated treatment with 3.2
mg/kg/day morphine during phase 2 reduced expression of methadone’s ratedecreasing effects and increased expression of its rate-increasing effects. Thus, 1.0
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mg/kg methadone no longer depressed ICSS at any frequency of brain stimulation, but
rather produced facilitation of ICSS at intermediate frequencies (71-100 Hz). Similarly,
3.2 mg/kgdepressed ICSS across a narrower range of high frequencies during phase 2
(141-158 Hz), and it increased ICSS at intermediate frequencies (71-79 Hz). One of
eight subjects died before completion of this phase, so only seven rats completed
testing with all methadone doses in phase 2 and advanced to phase 3. During phase 3,
1.0 and 3.2 mg/kg methadone produced exclusive rate-increasing effects at the
intermediate frequencies 89-100 Hz and 63-89 Hz, respectively. A higher dose of 5.6
mg/kg methadone was introduced during this phase, and it produced biphasic effects
similar to the effects of 3.2 mg/kg during phase 2 (figure 4.2 e,f). Two subjects died
during high-dose morphine treatment in phase 3, so only 5 rats completed testing with
all methadone doses in this phase.
Effects of fentanyl on ICSS before and during chronic morphine. Figure 4.3
shows the effect of fentanyl on ICSS during phases 1-3. During phase 1, a low dose of
0.003 mg/kg fentanyl facilitated ICSS at one frequency (89 Hz), but only rate-decreasing
effects were produced by higher fentanyl doses of 0.01 mg/kg (158 Hz) and 0.03 mg/kg
(100-158) (figure 4.3 a,b). A lower fentanyl dose of 0.001 mg/kg was also tested, and it
did not produce any change in ICSS (data not shown). During phase 2, 0.003 mg/kg
fentanyl did not produce any significant change in ICSS compared to vehicle. However,
effects of 0.01 and 0.03 mg/kg fentanyl changed from exclusive depression of ICSS at
high frequencies during phase 1 to exclusive facilitation of ICSS at intermediate
frequencies during phase 2. Thus, fentanyl at 0.01 and 0.03 mg/kg produced exclusive
facilitation of ICSS at 89-100 Hz and 71-100 Hz, respectively (figure 4.3 c,d). A higher
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fentanyl dose of 0.1 mg/kg was also introduced during phase 2, and this dose nearly
eliminated responding and significantly reduced ICSS at the highest five frequencies
(100-158 Hz). One of six rats died during phase 2, so only five rats completed testing
with all fentanyl doses and advanced to phase 3. During the third phase, neither 0.003
nor 0.01 mg/kg morphine altered ICSS at any frequency. However, 0.03 mg/kg fentanyl
still facilitated ICSS at intermediate frequencies (71-100 Hz), and 0.1 mg/kg fentanyl still
depressed ICSS at high frequencies (112-158 Hz) (figure 3 e,f).
Effects of nalbuphine on ICSS before and during chronic morphine. Figure
4.4 shows the effects of nalbuphine on ICSS during phases 1-3. During phase 1,
nalbuphine primarily facilitated ICSS, although these effects were not monotonically
related to dose. Thus, exclusive facilitation of ICSS was produced by nalbuphine doses
of 0.1 (79 Hz), 0.32 (71-89 Hz) and 3.2 mg/kg (71-89 Hz), and the highest dose of 10
mg/kg produced biphasic effects (facilitation at 63-79 Hz and depression at 158 Hz).
Conversely, 1.0 mg/kg nalbuphine (the first dose tested) did not facilitate ICSS and
significantly depressed ICSS at the highest frequency (158 Hz). Repeated treatment
with 3.2 mg/kg/day morphine during phase 2 eliminated expression of nalbuphine’s ratedecreasing effects and enhanced the dose-dependence and magnitude of nalbuphine’s
rate-increasing effects. For example, 10 mg/kg nalbuphine facilitated ICSS at
frequencies of 63-100 Hz and did not depress ICSS at any frequency (figure 4.4 c,d).
During phase 3, nalbuphine produced similar effects consisting of exclusive ICSS
facilitation across all nalbuphine doses. In addition, diarrhea was observed in all
subjects after administration of 0.32-3.2 mg/kg nalbuphine (data not shown). One of six
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rats died during phase 3, so only five rats completed testing with all nalbuphine doses in
this phase.
Effect of naltrexone on ICSS during chronic 18 mg/kg/day morphine. At the
end of phase 3 and before the termination of the daily morphine treatment, 0.1 mg/kg
naltrexone was tested and results are shown in figure 4.5. Rate depression was the
predominant effect of naltrexone compared to vehicle, and it depressed ICSS at
frequencies of 112 and 126 Hz. Diarrhea was observed in all subjects after
administration of this dose of naltrexone.
Effect of methadone and nalbuphine after 2 weeks of morphine abstinence.
The effects of methadone (N=5) and nalbuphine (N=5) were redetermined beginning
after 3 weeks of morphine abstinence. As noted above, daily baseline ICSS recovered
toward pre-drug baseline levels within three days after termination of morphine
treatment (Figure 4.1), and daily baseline ICSS persisted at pre-drug baseline levels
throughout testing during abstinence. For example, for the 10 rats that completed
abstinence testing, the pre-drug control ± SEM number of stimulations per component
was 297.8 ± 83.6, and the mean number of stimulations per component during
abstinence testing was 293.0 ± 163.0. Figure 4.6 shows that methadone and
nalbuphine effects during abstinence testing were generally similar to their effects
during phase 2 testing. Thus, 0.32 mg/kg methadone did not significantly alter ICSS, 1.0
mg/kg methadone facilitated ICSS at intermediate frequencies (63-100 Hz), and 3.2
mg/kg methadone tended to produce biphasic effects, with facilitation at 71-79 Hz and a
non-significant decrease in mean ICSS rates at high frequencies (126-158 Hz) (figure
4.6 a,b). Similarly, nalbuphine produced a dose-dependent facilitation of ICSS, although
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effects of the lowest dose of 0.1 mg/kg nalbuphine did not achieve statistical
significance (figure 4.6 c,d). In addition, diarrhea was not detected after any nalbuphine
dose during this phase (data not shown).

4.4. Summary
This study examined the impact of graded morphine exposure on changes in
ICSS produced by agonists with high efficacy (methadone), intermediate efficacy
(fentanyl) or low efficacy (nalbuphine) at mu opioid receptors. There were three main
findings. First, in agreement with previous results (Altarifi et al., 2012) the higher
efficacy mu agonists methadone and fentanyl produced primarily rate-decreasing
effects in opioid-naïve subjects, whereas the low-efficacy mu agonist nalbuphine
produced primarily rate-increasing effects that did not vary systematically as a function
of dose. Second, repeated morphine produced cross tolerance to the rate-decreasing
effects and enhanced expression of the rate-increasing effects of all three mu agonists.
Lastly, the daily morphine dosing regimen used here produced withdrawal-associated
decreases in baseline ICSS determined approximately 23 hr after morphine. Repeated
morphine also enhanced rate-decreasing effects of the antagonist naltrexone. However,
this evidence of opioid dependence and withdrawal was not sufficient to account for
enhanced expression of mu agonist-induced rate-increasing effects. Taken together,
these results provide further evidence to suggest that repeated opioid exposure
increases the degree to which mu agonists produce abuse-related facilitation of ICSS.
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Figure 4.1
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Figure 4.1. ICSS performance before, during and after chronic morphine
treatment. ICSS curves were analyzed during pre-drug baseline sessions (grey dashed
line), daily baseline components from test sessions during phases 1-3, and day 3 after
termination of chronic morphine treatment (WD3: Withdrawal Day 3) for subjects that
finished all three phases. The left panel shows ICSS frequency-rate curves. Horizontal
axes: frequency of electrical brain stimulation in hertz (log scale). Vertical axes: ICSS
rate expressed as percent maximum control rate (%MCR). Filled symbols indicate
frequencies at which ICSS rates were lower than those observed during the pre-drug
baseline components, as determined by the Holm-Sidak post-hoc test following a
significant two-way ANOVA. Summary data in the right panel show the total number of
stimulations per test component expressed as a percentage of total pre-drug baseline
control stimulations. Horizontal axes: phase of the treatment. Vertical axes: percent
control stimulations per test component. Upward and/or downward arrows indicate the
presence and valence of significant differences from pre-drug baseline as determined
by analyses of frequency-rate data in the left panel. Thus, upward arrows indicate
significant facilitation of ICSS at ≥1 frequency of the frequency-rate curve, whereas
downward arrows indicate significant depression of ICSS at ≥1 frequency of the
frequency-rate curve. ANOVA results were as follows: Significant main effect of
frequency [F(9,126)=158.1; P<0.001], significant main effect of phase [F(3,42)=11.0;
P<0.001], and significant phase X frequency interaction [F(27,378)=4.9; P<0.001]. All
points show mean ± SEM for 15 rats.
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Figure 4.2
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Figure 4.2. Effects of methadone on ICSS before and during chronic morphine
treatment. Methadone doses (or vehicle) were administered during treatment with
repeated vehicle (phase 1; a,b), repeated 3.2 mg/kg/day morphine (phase 2; c,d), and
repeated 18 mg/kg/day morphine (phase 3; e,f). Left panels show full frequency-rate
curves. Left abscissae: frequency of electrical brain stimulation in hertz (log scale). Left
ordinates: ICSS rate expressed as percent maximum control rate (%MCR). Filled
symbols indicate frequencies at which ICSS rates after methadone were different than
those observed after vehicle, as determined by the Holm-Sidak post-hoc test following a
significant two-way ANOVA. Summary data in the right panels show the total number of
stimulations per test component expressed as a percentage of total pre-drug baseline
control stimulations. Abscissae: dose of methadone in mg/kg. Ordinates: percent control
stimulations per test component. Upward and/or downward arrows indicate the
presence and valence of significant differences from vehicle treatment as determined by
analyses of frequency-rate data in the left panels. All points show mean ± SEM for 5-8
rats. For description of axes and symbols, please refer to figure 1. ANOVA results were
as follows: Chronic vehicle: Significant main effect of frequency [F(9,63)=31.4;
P<0.001], significant main effect of dose [F(3,21)=9.9; P<0.001], and significant dose X
frequency interaction [F(27,189)=9.1; P<0.001]. Repeated 3.2 mg/kg/day morphine:
Significant main effect of frequency [F(9,54)=67.2; P<0.001], no significant main effect
of dose [F(3,18)=2.6; P=0.086], and significant dose X frequency interaction
[F(27,162)=11.2; P<0.001]. Repeated 18 mg/kg/day morphine: Significant main effect of
frequency [F(9,36)=91.5; P<0.001], no significant main effect of dose [F(4,16)=1.2;
P=0.365], and significant dose X frequency interaction [F(36,144)=10.4; P<0.001].
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Figure 4.3
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Figure 4.3. Effects of fentanyl on ICSS before and during chronic morphine
treatment. Fentanyl doses (or vehicle) were administered during treatment with
repeated vehicle (phase 1; a,b), repeated 3.2 mg/kg/day morphine (phase 2; c,d), and
repeated 18 mg/kg/day morphine (phase 3; e,f). All points show mean ± SEM for 5-6
rats. For description of axes and symbols, please refer to figure 2. ANOVA results were
as follows: Chronic vehicle: Significant main effect of frequency [F(9,45)=93.2;
P<0.001], significant main effect of dose [F(3,15)=4.3; P=0.022], and significant dose X
frequency interaction [F(27,135)=5.6; P<0.001]. Repeated 3.2 mg/kg/day morphine:
Significant main effect of frequency [F(9,45)=30.6; P<0.001], significant main effect of
dose [F(4,20)=15.7; P<0.001], and significant dose X frequency interaction
[F(36,180)=10.0; P<0.001]. Repeated 18 mg/kg/day morphine: Significant main effect of
frequency [F(9,36)=37.7; P<0.001], significant main effect of dose [F(4,16)=12.1;
P<0.001], and significant dose X frequency interaction [F(36,144)=5.3; P<0.001].
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Figure 4.4. Effects of nalbuphine on ICSS before and during chronic morphine
treatment. Nalbuphine doses (or vehicle) were administered during treatment with
repeated vehicle (phase 1; a,b), repeated 3.2 mg/kg/day morphine (phase 2; c,d), and
repeated 18 mg/kg/day morphine (phase 3; e,f). All points show mean ± SEM for 5-6
rats. For description of axes and symbols, please refer to figure 2. ANOVA results were
as follows: Chronic vehicle: Significant main effect of frequency [F(9,45)=63.0;
P<0.001], significant main effect of dose [F(5,25)=6.6; P<0.001], and significant dose X
frequency interaction [F(45,225)=3.0; P<0.001]. Repeated 3.2 mg/kg/day morphine:
Significant main effect of frequency [F(9,45)=18.9; P<0.001], significant main effect of
dose [F(5,25)=14.9; P<0.001], and significant dose X frequency interaction
[F(45,225)=2.9; P<0.001]. Repeated 18 mg/kg/day morphine: Significant main effect of
frequency [F(9,36)=13.2; P<0.001], significant main effect of dose [F(5,20)=9.0;
P<0.001], but no significant dose X frequency interaction [F(45,180)=1.0; P=0.532].
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Figure 4.5

Figure 4.5. Effects of 0.1 mg/kg naltrexone (NLTX) on ICSS during chronic 18
mg/kg/day morphine treatment (phase 3). All points show mean ± SEM for 15 rats
from all groups. For description of axes and symbols, please refer to figure 2. There
was significant main effect of frequency [F(9,126)=74.0; P<0.001], significant main
effect of treatment [F(1,14)=6.7; P=0.021], and significant dose X frequency interaction
[F(9,126)=3.7; P<0.001].
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Figure 4.6

Figure 4.6. Effects of methadone and nalbuphine on ICSS after termination of
repeated morphine treatment. Methadone (a,b) and nalbuphine (c,d) were tested after
3 weeks of morphine abstinence. All points show mean ± SEM for 5 rats. For
description of axes and symbols, please refer to figure 2. ANOVA results were as
follows: Methadone: Significant main effect of frequency [F(9,36)=22.6; P<0.001], no
significant main effect of dose [F(3,12)=2.6; P=0.097], and significant dose X frequency
interaction [F(27,108)=5.7; P<0.001]. Nalbuphine: Significant main effect of frequency
[F(9,36)=7.8; P<0.001], significant main effect of dose [F(5,20)=11.3; P<0.001], and
significant dose X frequency interaction [F(45,180)=2.0; P<0.001].
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Table 4.1. Summary table showing the experimental design, drug doses, and
number of subjects used in each group
Group

1

Test Drug

Methadone
(n = 5-8)

Fentanyl

Variable

Phase I

Phase II

Phase III

Phase IV

Chronic
treatment

Vehicle

3.2 mg/kg/day
morphine

18 mg/kg/day
morphine

Vehicle

Doses (mg/kg)

0.032-3.2

0.032-3.2

0.032-5.6

0.032-3.2

Chronic
treatment

Vehicle

3.2 mg/kg/day
morphine

18 mg/kg/day
morphine

N/A a

Doses (mg/kg)

0.001-0.03

0.001-0.1

0.001-0.1

N/A a

Chronic
treatment

Vehicle

3.2 mg/kg/day
morphine

18 mg/kg/day
morphine

Vehicle

Doses

0.1-10

0.1-10

0.1-10

0.1-10

2
(n = 5-6)

3

a

Nalbuphine
(n = 5-6)

N/A=not applicable. Subjects were euthanized at the end of phase III
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Table 4.2. Maximum control rates (MCR) and total stimulations obtained during
pre-drug Baseline

Group (Drug)

MCR (±SEM)

Control Total Stimulations (±SEM)

1 (Methadone)

56.5 (±6.8)

282.5 (±61.9)

2 (Fentanyl)

55.8 (±11.1)

263.5 (±52.6)

3 (Nalbuphine)

59.7 (±12.7)

315.5 (±96.0)
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CHAPTER FIVE
Effects of mu opioid receptor agonists in assays
of acute pain-stimulated and pain-depressed behavior in rats

5.1. Introduction
Pain-related behaviors can be assigned to two general categories that we have
called “pain-stimulated behaviors” and “pain-depressed behaviors” (Negus et al., 2010).
Most assays that are used to measure pain in laboratory animals fall under painstimulated behaviors, such as tail-withdrawal, paw withdrawal, and stretching. Although
these types of assays helped in identifying pain neurobiology, identifying possible
targets for future drug analgesics, and studying the pharmacology of current analgesics,
they failed to generate more efficient and safer analgesics than those currently used in
pain medicine, such as opioids and NSAIDs. One reason behind this discrepancy is that
animal ‘pain’ models do not simulate multidimensional clinical pain conditions (Mao,
2012). On the other hand, pain-depressed behaviors may be more clinically relevant,
but they have received little attention in preclinical research. Thus, preclinical assays of
pain-depressed behaviors, such as feeding and locomotion, may be a better target to
enhance pain medicine.
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It has been shown previously that intraperitoneal injection of dilute lactic acid
produced depression in ICSS and pretreatment with morphine was able to block the
acid effect (Pereira Do Carmo et al., 2009). Depression of ICSS can be classified as an
example of pain-depressed behaviors, and the effect of morphine may indicate the
sensitivity of this assay to clinically used analgesics. In the current study, lactic acid was
used as the noxious stimulus because hydrogen ions can directly activate acid-sensitive
ion channels which have a particular relevance in the development and maintenance of
inflammatory pain (Karczewski et al., 2010), and we wanted to expand these findings by
testing the pharmacology of mu opioid agonists with and without noxious stimulus in
ICSS in comparison to an assay of acid-stimulated stretching. We tested a variety of
clinically used opioid agonists that have different efficacy at the mu receptor. Also,
selected agonists were tested after noxious stimulus intensity manipulation.

5.2. Methods

5.2.1. Subjects
Subjects are similar to those described on section 2.2.1.

5.2.2. Assay of intracranial self-stimulation
Intracranial self-stimulation electrode implantation and behavioral procedure are
similar to those described on section 2.2.2.
Testing: ICSS testing was conducted in two phases. First, the effects of
methadone (0.032-1.0 mg/kg), fentanyl (0.0032-0.032 mg/kg), morphine (0.1-3.2
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mg/kg), hydrocodone (0.1-3.2 mg/kg), buprenorphine (0.001-0.032 mg/kg) and
nalbuphine (0.1-1.0 mg/kg) were examined as pretreatments to 1.8% lactic acid or acid
vehicle (sterile water). Each drug was tested in a separate group of 5-6 rats that were
opioid-naïve at the start of the study. ICSS test sessions consisted of 5 sequential
components with a 30 min time out between the first three and last two components.
The first component of each test session was considered to be an acclimation
component, and data were discarded. Data from the second and third ‘‘baseline’’
components were used to calculate baseline parameters of frequency-rate curves for
that session (see Data Analysis). Following these baseline components and during the
time out, test drug or its vehicle was administered subcutaneously as a 30-minute
pretreatment to 1.8% lactic acid or its vehicle (IP in a volume of 1.0 ml/kg). Two
sequential test components were conducted immediately after the second injection.
Test sessions were conducted on Tuesdays and Fridays, with one test day each week
devoted to evaluation of one dose of one opioid as a pretreatment to lactic acid, and the
other day devoted to evaluation of the same dose of the same opioid as a pretreatment
to acid vehicle. For all drugs, doses were delivered in a mixed order across rats. Threecomponent training sessions were conducted during other weekdays.
The second phase of the study was designed to compare effects of methadone
and nalbuphine on depression of ICSS produced by a higher intensity noxious stimulus.
First, 13 naïve rats were treated at weekly intervals with subcutaneous saline as a 30minute pretreatment to vehicle, 0.56%, 1.8%, or 5.6% lactic acid (in order of testing; IP
in a volume of 1.0 ml/kg). Test sessions began with three baseline components
followed first by delivery of injections during a 30 min time out and then by two
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consecutive test components. Subsequently, the rats were divided into two groups, and
the effect of 5.6% lactic acid on ICSS were redetermined after pretreatment with
methadone (0.1 and 1.0 mg/kg; N=6) or nalbuphine (1.0 or 10 mg/kg; N=7). For each
drug, the lowest dose was the dose that produced peak antinociception against 1.8%
lactic acid in the first phase of the study, and this was the first dose tested. Rats were
then tested a week later with a 10-fold higher dose of each drug.
Data Analysis. The primary dependent variable was the reinforcement rate in
stimulations/trial during each frequency trial. To normalize these raw data,
reinforcement rates from each trial were converted to Percent Maximum Control Rate
(%MCR) for that rat on that day. The maximum control rate was determined during
control components of each test session and was defined as the mean of the maximal
rates observed in any frequency trial during the second and third control components.
Thus, %MCR for each trial was calculated as (Reinforcement Rate During a Frequency
Trial ÷ Maximum Control Rate) × 100. Normalized data from the frequency trials of each
pair of consecutive test components were then averaged across rats for display and for
statistical analysis using two-way ANOVA, with drug dose or time as one factor and
ICSS frequency as the other factor. A significant ANOVA was followed by a Holm-Sidak
post hoc test, and the criterion for significance was set at p < 0.05.
To provide an additional summary of ICSS performance, the total number of
stimulations obtained at all frequencies was summed for each test component and
averaged across the two test components of each experimental session in each rat.
Data for total stimulations per component were then expressed as a percentage of the
baseline number of stimulations per component in each rat and averaged across rats.
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These data were also used to quantify blockade of acid-induced depression of ICSS.
Specifically, "percent acid blockade" was quantified using the equation [(testacid)/(baseline-acid)]*100, where "test" was the total number of ICSS stimulations after
treatment with drug + acid, "acid" was the total number of stimulations after acid alone,
and "baseline" was the total number of stimulations in the absence drug or acid. For all
drugs producing greater than 50% acid blockade, linear regression was used to
calculate an ED50 and 95% confidence limits, with ED50 defined as the effective dose
producing 50% acid blockade. For drugs that produced inverted U-shaped dose-effect
curves (methadone, fentanyl, morphine), the ED50 value was determined from the
ascending limb of the dose-effect curve. ED50 values were considered to be
significantly different if 95% confidence limits did not overlap.

5.2.3. Assay of lactic acid-stimulated stretching
Behavioral Procedure. Test sessions were conducted once per week. Test
drugs were administered subcutaneously 30 minutes prior to treatment with 1.8% lactic
acid (IP in a volume of 1.0 ml/kg). Immediately after acid injection, rats were placed into
acrylic test chambers (31.0 X 20.1 X 20.0 cm) for 30-minute observation periods. A
stretch was operationally defined as a contraction of the abdomen followed by extension
of the hind limbs, and the number of stretches during the observation period was
counted. Effects of methadone (0.1-1.0 mg/kg), fentanyl (0.0032-0.032 mg/kg),
morphine (0.1-1.0 mg/kg), hydrocodone (0.1-1.0 mg/kg), buprenorphine (0.00032-0.01
mg/kg) and nalbuphine (0.1-1.0 mg/kg) were examined in separate groups of 5-8 rats.
Drug doses were tested in a mixed order across rats.
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Similar to ICSS experiments, a separate group of naïve rats (n=7) was treated
with subcutaneous saline as a 30-minute pretreatment to vehicle (water), 0.56%, 1.8%,
or 5.6% lactic acid (in order of testing; IP in a volume of 1.0 ml/kg). After acid
administration, rats were observed for 30 min, and the total number of stretches was
counted as described previously.
Data Analysis. The primary dependent variable was the number of stretches
counted during each observation period in each rat. To normalize these data, raw
counts were converted to percent vehicle control using the equation (drug/vehicle)X100,
where "drug" was the number of writhes observed after drug + acid, and "vehicle" was
the number of writhes after drug vehicle + acid. These data were then averaged across
rats. For all drugs producing greater than 50% reduction in stretching, linear regression
was used to calculate an ED50 and 95% confidence limits, with ED50 defined as the
effective dose producing 50% control writhing.
To evaluate significance during tests with different acid concentrations, data were
averaged across rats, and one way-ANOVA was used for statistical analysis. A
significant ANOVA was followed by a Dunnett post-hoc test with P < 0.05.

5.2.4. Drugs
Methadone HCl, fentanyl HCl, morphine sulfate, hydrocodone bitartrate and
buprenorphine HCl were provided by the National Institute on Drug Abuse Drug Supply
Program (Bethesda, MD). Nalbuphine HCl was provided by Dr. Kenner Rice (Chemical
Biology Branch, National Institute on Drug Abuse and National Institute on Alcohol
Abuse and Alcoholism, Bethesda, MD). All opioids were dissolved in saline and
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delivered SC in a volume of 1 ml/kg body weight. Lactic acid was purchased from
Sigma Chemical Co. (St. Louis, MO), diluted in sterile water, and administered IP in a
volume of 1 ml/kg body weight.

5.3. Results

Effects of Mu Agonists in the Assay of Acid-Stimulated Stretching
Across all 35 rats used for studies of acid-stimulated stretching, IP administration
of 1.8% lactic acid (1.0 ml/ kg) after drug vehicle pretreatments elicited a mean ± SEM
of 13.1 ± 4.1 writhes. The absolute number of control writhes elicited by acid after
vehicle pretreatment in each group is reported in the legend of Figure 5.1. All 6 mu
opioid receptor agonists produced a dose-dependent decrease in acid-stimulated
stretching, and ED50 values are shown in Table 5.1.

Effects of Mu Agonists in the Assay of Acid-Depressed ICSS
Effects of the lactic acid noxious stimulus on ICSS. Figure 5.2 shows effects
of the same noxious stimulus (IP injection of 1.8% lactic acid) on ICSS. During each test
session, a ‘‘baseline’’ frequency-rate curve was determined before experimental
treatments to permit determination of the MCR for that session. Over the course of the
entire study, the mean ± SEM MCR was 61.49 ± 8.91 stimulations per trial.
Reinforcement rates during each frequency trial of a session were then expressed as a
percentage of that session’s MCR, and the average frequency-rate curve for all studies
with drug vehicle + acid vehicle is shown in Figure 2. Maximum reinforcement rates
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were usually observed at the highest stimulation frequencies (112-158 Hz), and
responding generally decreased in a frequency-dependent manner. Administration of
1.8% lactic acid depressed ICSS, producing a rightward shift in the frequency-rate
curve. Figure 5.2 also shows summary data for the total number of stimulations
delivered across all 10 frequencies during each component. The overall mean ± SEM
baseline number of stimulations per component for all rats in the study was 319 ± 79.5.
Total ICSS after treatment with vehicle + acid vehicle was nearly identical to baseline
pre-drug ICSS, but acid treatment decreased the number of stimulations per
component. This acid-induced depression of ICSS provided a measure of pain-related
behavioral depression, and opioids were evaluated for their ability to block this acidinduced depression of ICSS.
Methadone and fentanyl. Figure 5.3 shows that methadone and fentanyl dosedependently and completely blocked 1.8% acid-induced depression of ICSS at or near
doses that also facilitated control ICSS in the absence of the noxious acid stimulus.
When administered as a pretreatment to acid vehicle, methadone doses of 0.032-0.32
mg/kg produced leftward shifts in the ICSS frequency-rate curve and significant
facilitation of ICSS at intermediate frequencies of brain stimulation, whereas the highest
dose of 1.0 mg/kg methadone only depressed ICSS at the highest two frequency (141158 Hz) (Fig 5.3A). Similarly, when administered as a pretreatment to 1.8% lactic acid,
methadone increased ICSS responding and ameliorated acid-induced depression of
ICSS (Fig 5.3B). Significant increases in ICSS responding were observed after
pretreatment with all methadone doses at a broad range of frequencies ranging from
71-112 Hz, and 0.1 mg/kg was the dose that produced the maximal attenuation of acid-
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induced depression of ICSS. The highest dose of 1.0 mg/kg methadone also decreased
ICSS at 158 Hz after acid pretreatment.
Pretreatment with fentanyl also non-selectively increased ICSS responding in the
absence (Fig 5.3D) or presence of the acid noxious stimulus (Fig 5.3E). Doses of 0.01
and 0.032 mg/kg fentanyl significantly increased rates of reinforcement under both
conditions across a broad range of frequencies from 79-112 Hz, and these effects of
fentanyl are summarized in Figure 5.3F. Overall, methadone and fentanyl produced
nonselective facilitation of ICSS in the absence or presence of acid, although both drugs
were more efficacious to facilitate ICSS during acid treatment compared to acid vehicle
treatment.
Morphine and hydrocodone. Figure 5.4 shows effects of morphine and
hydrocodone on ICSS in the absence or presence of the acid noxious stimulus. When
administered as a pretreatment to acid vehicle, morphine doses of 0.1-1.0 mg/kg had no
significant effect on ICSS, but a higher dose of 3.2 mg/kg significantly depressed high
rates of ICSS maintained by some high brain stimulation frequencies (Fig. 5.4A). When
administered as a pretreatment to lactic acid, morphine doses of 0.1-1.0 mg/kg dosedependently blocked acid-induced depression of ICSS; the higher dose of 3.2 mg/kg
also attenuated acid-induced depression of ICSS, though to a lesser degree than 1.0
mg/kg (Fig. 5.4B). In contrast to morphine, hydrocodone doses of 0.1-3.2 mg/kg dose
dependently facilitated ICSS in the absence of the noxious stimulus (Fig. 5.4D) and also
dose-dependently blocked acid-induced depression of ICSS (Fig. 5.4E). No dose of
hydrocodone depressed ICSS at any frequency in the absence or presence of the
noxious stimulus. Overall, both morphine and hydrocodone blocked acid-induced
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depression of ICSS, although with hydrocodone, this was accompanied by facilitation of
ICSS in the absence of the noxious stimulus (Fig. 5.4C and 5.4F).
Buprenorphine and nalbuphine. Figure 5.5 shows that, similar to
hydrocodone, the lower efficacy mu agonists buprenorphine and nalbuphine produced
dose-dependent facilitation of ICSS in the absence of the noxious stimulus (Fig. 5.5A
and 5.5D) and also dose-dependently blocked acid-induced depression of ICSS (Fig.
5.5B and 5.5E). No dose of buprenorphine or nalbuphine depressed ICSS at any
frequency in the absence or presence of the noxious stimulus. Summary data for
buprenorphine and nalbuphine are shown in Figures 5.5C and 5.5F, respectively.
Opioid ED50 values to block acid-induced depression of ICSS. Figure 6
shows effects of all 6 opioids expressed as ‘‘percent blockade” in the assay of acidinduced depression of ICSS. For the highest efficacy drugs methadone, fentanyl and
morphine, an inverted U-shape curve was produced, such that peak blockade of acidinduced ICSS depression was achieved with intermediate doses (Fig. 5.6A).
Conversely, hydrocodone, buprenorphine and nalbuphine produced dose-dependent
blockade of acid-induced depression of ICSS across all doses examined (Fig. 5.6B).
Table 5.1 shows ED50 values for the effects of each drug (derived from the ascending
limbs of the dose-effect curves for methadone, fentanyl and morphine).

Effects of Noxious Stimulus Intensity
Figure 5.7 shows the effect of different concentration of lactic acid on acidstimulated writhing and acid-induced depression of ICSS. Vehicle produced 2.57 ± 1.72
stretches during the 30-min observation period, and vehicle did not facilitate or depress
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ICSS compared to baseline. Lactic acid produced a bitonic effect on acid-stimulated
stretching, such that 0.56% and 5.6% acid did not produce significant stimulation of
stretching relative to vehicle, whereas 1.8% acid did produce significant stimulation of
stretching (Fig. 5.7A). Because the high concentration of 5.6% lactic acid did not
stimulate a significant stretching response, opioid effects were not examined. On the
other hand, lactic acid produced a concentration-dependent depression of ICSS that
was significant after 1.8 and 5.6% acid (Fig. 5.7B). Table 5.1 shows that increasing the
noxious stimulus intensity to 5.6% lactic acid produced a decrease in the potency of
both methadone (approximately 10-fold) and nalbuphine (approximately 15-fold) to
block acid-induced depression of ICSS.

5.4. Summary
This study examined the effects of mu opioid agonists in assays of acidstimulated stretching and acid-depressed ICSS in rats. Two independent variables were
manipulated in each assay: the efficacy of mu agonists at the mu receptor, and the
noxious stimulus intensity. Intraperitoneal injection of lactic acid produced
concentration-dependent decrease in ICSS, and an inverted U-shape stimulation of
stretching with a peak effect after 1.8% lactic acid. Pretreatment with mu agonists
blocked acid-stimulated stretching and acid-induced depression of ICSS in the presence
of 1.8% acid, regardless of the efficacy of the agonist. Increasing the intensity of the
noxious stimulus decreased the potency of high and low mu opioid agonists to block
acid-induced depression of ICSS. In the absence of the noxious stimulus and consistent
with previous findings (Altarifi et al., 2012), mu agonists tended to produce facilitation of
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ICSS, which did not vary systematically as a function of drug efficacy at the mu
receptor. Overall, clinically used mu opioid analgesics are effective to produce
antinociception in assays of pain-stimulated and pain-depressed behaviors.
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Figure 5.1

Figure 5.1. Effects of mu opioid agonists in the assay of acid-stimulated
stretching. Abscissae: Dose in mg/kg. Ordinates: Percent control stretches. All points
show mean data ± SEM from 5 to 8 rats, and ED50 values are reported in Table 5.1.
The mean ± SEM number of control stretches for each group were as follows:
methadone, 13.3 ± 4.3; fentanyl, 13.9 ± 2.7; morphine, 14.0 ± 7.6; hydrocodone, 12.7 ±
3.1; buprenorphine, 12.3 ± 4.1; nalbuphine, 12.9 ± 2.8.
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Figure 5.2

Figure 5.2. Depression of ICSS by 1.8% lactic acid. Left panel (A) compares effects
of pretreatment with vehicle + vehicle (Veh + Veh) and vehicle + 1.8% lactic acid (Veh+
1.8% LA) on full frequency-rate curves for all 35 rats used in the first phase of ICSS
experiments. Abscissa: Frequency of electrical brain stimulation in Hz. Ordinate: ICSS
rate expressed as percent maximum control response rate (%MCR). Two-way ANOVA
indicated a significant main effect of frequency [F(9,306) = 295.4, P < .001] and acid
treatment [F(1,34) = 86.8, P < .001], and the interaction was also significant [F(9,306) =
10.2, P <0 .001]. The acid noxious stimulus significantly depressed ICSS at all
frequencies (Holm-Sidak post hoc test, P < .05). Right panel (B) shows summary data
for lactic acid effects on the total number of stimulations per component. Abscissa:
Pretreatment conditions. Ordinate: Percent baseline number of stimulations per
component. The downward arrow indicates that lactic acid produced a signiﬁcant
decrease in ICSS at 1 or more frequencies in the full frequency-rate curve.
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Figure 5.3
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Figure 5.3. Effects of the methadone (panels A–C, N = 6) and fentanyl (panels D–F,
N = 5) on control and 1.8% acid-depressed ICSS. Left and center panels show drug
effects on full frequency-rate curves when drugs were administered as a pretreatment to
vehicle (Left panels A, D) or 1.8% lactic acid (center panels B, E). Abscissae:
Frequency of electrical brain stimulation in Hz. Ordinates: Percent maximum control
response rate (%MCR). Filled symbols indicate a signiﬁcant difference from Veh+Veh
(A, D) or Veh+LA (B, E) (Holm-Sidak post hoc test, P < .05). Right panels (C, F) show
summary data for drug effects on the total number of stimulations per component when
drugs were administered as a pretreatment to vehicle (open bars) or acid (ﬁlled bars),
and # signs indicate significant acid-induced depression of ICSS under drug vehicle
conditions (paired t-test). Abscissae: Dose of drug in mg/kg. Ordinate: Percent baseline
number of stimulations per component. Upward/downward arrows indicate that the drug
dose produced a signiﬁcant increase/decrease in ICSS at 1 or more frequencies in the
full frequency-rate curve. Statistical results for 2-way ANOVA of full frequency-rate
curves are as follows: (A) Signiﬁcant main effect of frequency [F(9,45) = 41.2, P < .001],
dose [F(4,20) = 5.9, P = .003], and interaction [F(36,180) = 3.0, P < 0.001]. (B)
Signiﬁcant main effect of frequency [F(9,45) = 41.2, P < .001], dose [F(4,20) = 3.8, P =
.018], and interaction [F(36,180) = 4.2, P < 0.001]. (D) Signiﬁcant main effect of
frequency [F(9,36) = 72.8, P < .001], but not dose [F(3,12) = 1.1, P = 0.384]; the
interaction was signiﬁcant [F(27,108) = 4.3, P < 0.001]. (E) Signiﬁcant main effect of
frequency [F(9,36) = 63.5, P < .001] and dose [F(3,12) = 6.1, P = 0.009] and [F(27,108)
= 1.7, P = .030].
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Figure 5.4

Figure 5.4. Effects of morphine (panels A–C, N = 6) and hydrocodone (panels D–F,
N = 6) on control and 1.8% acid-depressed ICSS. Details as in Figure 5.3. Statistical
results for 2-way ANOVA of full frequency-rate curves are as follows: (A) Signiﬁcant
main effect of frequency [F(9,45) = 91.9, P < .001], but not dose [F(4,20) = 1.2, P =
0.356]; the interaction was signiﬁcant [F(36,180) = 2.2, P < 0.001]. (B) Signiﬁcant main
effects of frequency [F(9,45) = 56.8, P < .001], dose [F(4,20) = 8.2, P < 0.001], and
interaction [F(36,180) = 2.7, P < 0.001. (D) Signiﬁcant main effect of frequency [F(9,45)
= 71.0, P < .001], dose [F(4,20) = 8.0, P < .001], and interaction [F(36,180) = 5.6, P <
.001]. (E) Signiﬁcant main effect of frequency [F(9,45) = 70.0, P < .001], dose [F(4,20) =
9.4, P < 0.001], and interaction [F(36,180) = 5.8, P < .001].
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Figure 5.5

Figure 5.5. Effects of buprenorphine (panels A–C, N = 6) and nalbuphine (panels
D–F, N = 6) on control and 1.8% acid-depressed ICSS. Details as in Figure 5.3.
Statistical results for 2-way ANOVA of full frequency-rate curves are as follows: (A)
Signiﬁcant main effect of frequency [F(9,45) = 70.6, P < .001], dose [F(4,20) = 2.9, P =
.049], and interaction [F(36,180) = 3.8, P < .001]. (B) Signiﬁcant main effects of
frequency [F(9,45) = 37.9, P < .001], dose [F(4,20) = 4.2, P = 0.012], and interaction
[F(36,180) = 2.1, P < 0.001]. (D) Signiﬁcant main effect of frequency [F(9,45) = 91.5, P
< .001], but not dose [F(3,15) = 1.5, P = 0.261]; the interaction was signiﬁcant
[F(27,135) = 2.9, P < .001]. (E) Signiﬁcant main effect of frequency [F(9,45) = 152.2, P <
.001], dose [F(3,15) = 5.1, P =0.012], and interaction [F(27,135) = 2.9, P < .001].
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Figure 5.6

Figure 5.6. Dose-effect curves for mu agonist blockade of acid-induced
depression of ICSS. Abscissae: Dose in mg/kg. Ordinates: Percent blockade of acidinduced depression of ICSS, calculated as described in Methods. All points show mean
data ± SEM from 5 to 6 rats, and ED50 values are reported in Table 5.1.
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Figure 5.7

Figure 5.7. Effect of acid concentration on acid-stimulated stretching (left panel)
and acid-depressed ICSS (right panel). Abscissae: lactic acid concentration
administered IP; Left ordinate: number of stretches during the 30-min observation
period; Right ordinate: Percent baseline number of stimulations per component. Oneway ANOVA (with Dunnett post-hoc test; P < 0.05) revealed the following results: (A)
significant effect of concentration [F(6,18) = 16.7, P < 0.001]. (B) significant effect of
acid concentration [F(12,36) = 22.3, P < 0.001]. # indicate conditions under which total
number of stimulations was significantly different from 0% (vehicle).
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Table 5.1. ED50 Values in mg/kg (95% Conﬁdence Limits) for mu opioid agonists to
produce antinociception in the assays of acid-stimulated stretching or acid-induced
depression of ICSS.
Acid-Stimulated
Stretching

Acid-Depressed ICSS

Methadone

0.272 (0.145-0.511)

0.051 (0.030-0.085)*

Fentanyl

0.008 (0.006-0.011)

0.004 (0.003-0.006)*

Morphine

0.171 (0.097-0.301)

0.124 (0.070-0.218)

Hydrocodone

0.343 (0.236-0.501)

0.239 (0.161-0.355)

Buprenorphine

0.002 (0.001-0.005)

0.004 (0.002-0.008)

Nalbuphine

0.217 (0.152-0.309)

0.328 (0.130-0.826)

Methadone

Not Tested

0.51 (0.08-3.46)

Nalbuphine

Not Tested

4.90 (1.52-15.86)

1.8% Lactic Acid

5.6% Lactic Acid

* Indicates significantly different from acid-stimulated stretching as indicated by nonoverlapping confidence limits
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CHAPTER SIX
Morphine antinociception is resistant to tolerance
in an assay of pain-depressed intracranial self-stimulation

6.1. Introduction
Data from chapter 4 show that repeated morphine produced tolerance to its own
rate-decreasing effects. If rate-decreasing effects contribute to morphine-induced
antinociception in assays of pain-stimulated behavior, then repeated morphine might
also produce tolerance to morphine effects in these assays. Conversely, if ratedecreasing effects do not contribute to morphine antinociception in assays of paindepressed behavior, then repeated morphine might not produce tolerance to morphine
antinociception in these assays; rather, repeated morphine might even enhance
antinociception in these assays by producing tolerance to rate-decreasing effects that
initially oppose and limit expression of antinociception. Thus, the hypothesis was that
morphine would maintain or increase its antinociceptive potency in the assay of acidinduced depression of ICSS, but that tolerance would develop to morphine
antinociception in the assay of acid-stimulated stretching.
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6.2. Methods

6.2.1. Subjects
Subjects are similar to those described on section 2.2.1.

6.2.2. Assay of intracranial self-stimulation
Intracranial self-stimulation electrode implantation and behavioral procedure are
similar to those described on section 2.2.2.
Testing: Once training and habituation to saline injections were completed, all
rats received a single injection of 1.8% lactic acid to confirm sensitivity to acid-induced
depression of ICSS prior to further testing. Next, “pre-drug baseline” sessions were
conducted over a period of 3 consecutive days to establish baseline ICSS performance
before administration of any dose of morphine. Each pre-drug baseline session
consisted of 3 components as described in section 2.2.2, after which chronic treatment
was initiated. Rats were divided into two groups that received either repeated morphine
or repeated vehicle for 7 consecutive days. Rats receiving repeated morphine were
treated with 3.2 mg/kg/day on days 1 and 2, 5.6 mg/kg/day on days 3 and 4, and 10
mg/kg/day on days 5, 6, and 7. The control group received daily vehicle (saline)
injections. Three ICSS components were conducted before each daily injection, and
two additional ICSS components were conducted beginning 30 min after each injection.
On days 8, 10, 12, and 14, all animals in both groups were tested with a sequence of
four treatments: (1) morphine vehicle + acid vehicle, (2) morphine vehicle + 1.8% lactic
acid, (3) 1.0 mg/kg morphine + acid vehicle”, or (4) 1.0 mg/kg morphine + 1.8% lactic
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acid. Morphine or its vehicle was administered 30 min before acid or its vehicle, and
treatment order was randomized in a Latin-square design across animals. On each test
day, ICSS was evaluated during 3 baseline components, followed immediately by
subcutaneous treatment with 1.0 mg/kg morphine or its vehicle, after which subjects
were returned to their home cages. After 30 min, subjects were treated intraperitoneally
with 1.8% lactic acid or its vehicle and returned to the ICSS chambers for 2 ICSS test
components. Immediately after testing, subjects in the chronic morphine group received
a supplemental injection of morphine (either 9 or 10 mg/kg) to maintain the total daily
dose of 10 mg/kg/day. In addition, on the non-test days (i.e. Days 9, 11, and 13),
animals were maintained on 10 mg/kg/day morphine or vehicle, and ICSS components
were conducted before and after injections as on Days 1-7. Table 6.1 summarizes all
the treatments over the two-week chronic experiment.
Data analysis. The primary dependent measure was the total number of
stimulations delivered across all 10 frequency trials of each component. The first ICSS
component each day was considered to be a warm-up component, and data were
discarded. Baseline ICSS in each subject was determined by averaging the number of
stimulations per component during the second and third components across the 3 predrug baseline days before chronic treatment was initiated (6 total components).
Baseline ICSS values in the chronic saline and morphine groups were compared by ttest. Data collected during chronic treatment and testing were then normalized to these
baselines using the equation % Baseline Stimulations per Component = (Stimulations
per Test Component /Baseline) x 100. Statistical analysis focused on data from the test
components on Days 8, 10, 12 and 14. Data from these 2 test components were
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averaged within each rat to yield average % Baseline Stimulations per Component for
each treatment in each rat. Data for each treatment were then averaged across rats
and compared by two-way ANOVA, with acute treatment as one factor (1.0 mg/kg
morphine or vehicle + 1.8% acid or vehicle), and chronic treatment as the other factor
(10 mg/kg/day morphine or vehicle). A significant ANOVA was followed by the
Bonferroni post-hoc test, and the criterion for significance was set a priori at P < 0.05.

6.2.3 Assay of acid-stimulated stretching
To evaluate stretching behavior, rats were placed into acrylic test chambers (31.0
X 20.1 X 20.0 cm) for 30-minute observation periods. A stretch was operationally
defined as a contraction of the abdomen followed by extension of the hind limbs, and
the number of stretches during the observation period was counted. Initially, all rats
were evaluated for 30 min after a single injection of 1.8% lactic acid to confirm
sensitivity to acid-stimulated stretching prior to further testing. Subsequently, rats were
divided into two groups that received either repeated morphine or repeated vehicle for 7
consecutive days. As in the assay of acid-depressed ICSS, rats receiving repeated
morphine were treated with 3.2 mg/kg/day on days 1 and 2, 5.6 mg/kg/day on days 3
and 4, and 10 mg/kg/day on days 5, 6, and 7, whereas the control group received daily
vehicle (saline) injections. To mimic handling conditions in ICSS rats, subjects were
placed into a clean acrylic chamber for 30 minutes before each daily injection, returned
to their home cage for 30 min after each daily injection, and then placed back into the
acrylic chamber for another 30 minutes. On days 8, 10, 12, and 14, all rats in both
groups were tested with the same sequence of treatments that was tested in ICSS rats:
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(1) morphine vehicle + acid vehicle, (2) morphine vehicle + 1.8% lactic acid, (3) 1.0
mg/kg morphine + acid vehicle, or (4) 1.0 mg/kg morphine + 1.8% lactic acid. On each
test day, rats were placed into the acrylic observation chamber for 30 min, followed
immediately by subcutaneous treatment with 1.0 mg/kg morphine or its vehicle, and
subjects were then returned to their home cages. After 30 min, subjects were treated
intraperitoneally with 1.8% lactic acid or its vehicle and returned to the chamber for
observation of stretching. Immediately after testing, subjects in the chronic morphine
group received a supplemental injection of morphine to maintain the total daily dose of
10 mg/kg/day. In addition, on the non-treatment days (i.e. Days 9, 11, and 13), rats
were maintained on 10 mg/kg/day morphine or vehicle and exposed to the acrylic
chamber before and after injections as on Days 1-7.
Data Analysis. The primary dependent variable was the number of stretches
observed during the 30-minute observation period after treatments on test days 8, 10,
12 and 14. Data for each treatment were averaged across rats and compared by twoway ANOVA, with acute treatment as one factor (1.0 mg/kg morphine or vehicle + 1.8%
acid or vehicle), and chronic treatment as the other factor (10 mg/kg/day morphine or
vehicle). A significant ANOVA was followed by the Bonferroni post-hoc test, and the
criterion for significance was set a priori at P < 0.05.

6.2.4. Drugs
Morphine sulfate was provided by the National Institute on Drug Abuse Drug
Supply Program (Bethesda, Maryland, USA) and prepared in sterile saline for
subcutaneous injection. Lactic acid was purchased from Sigma Aldrich (St. Louis, MO)
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and diluted in sterile water for intraperitoneal injection. All injections were delivered in a
volume of 1.0 ml/kg.

6.3. Results
Assay of acid-stimulated stretching. Figure 6.1 shows the effects of different
acute treatments on stretching behavior in rats treated chronically with vehicle or
morphine. In the chronic vehicle group, 1.8% lactic acid stimulated a stretching
response, and 1.0 mg/kg morphine blocked acid-stimulated stretching while having no
effect on stretching in the absence of the noxious stimulus. In the chronic morphine
group, 1.8% lactic acid stimulated a significantly greater number of stretches than in the
chronic vehicle group. Moreover, tolerance developed to the antinociceptive effects of
1.0 mg/kg morphine, such that morphine no longer produced a significant decrease in
stretching. In addition, stretching after treatment with 1.0 mg/kg morphine + acid was
significantly greater in the chronic morphine group than in the chronic vehicle group.

Assay of acid-depressed ICSS. During baseline sessions, the mean ± SEM total
numbers of stimulations for the chronic vehicle group and chronic morphine group were
339.8 ± 37.8 and 312.9 ± 57.9 stimulations per component, respectively (t=0.34, not
significantly different). Figure 6.2 shows the effects of different acute treatments on
ICSS in rats treated chronically with vehicle or morphine. In the chronic vehicle group,
1.8% lactic acid significantly depressed ICSS, and 1.0 mg/kg morphine blocked acidinduced depression of ICSS while having no effect on ICSS in the absence of the
noxious stimulus. In the chronic morphine group, 1.8% lactic acid also depressed ICSS.
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Although mean rates of ICSS were lower after acid in the chronic morphine group than
in the chronic vehicle group, this difference was not statistically significant. Tolerance
did not develop to morphine antinociception in the chronic morphine group. Thus, as in
the chronic vehicle group, 1.0 mg/kg morphine blocked acid-induced depression of
ICSS at a dose that did not alter ICSS in the absence of the noxious stimulus. ICSS
after 1.0 mg/kg morphine + acid was not different in the chronic vehicle and chronic
morphine groups.

6.4. Summary
This study examined the hypothesis that morphine would maintain or increase its
antinociceptive potency in the assay of acid-induced depression of ICSS, but that
tolerance would develop to morphine antinociception in the assay of acid-stimulated
stretching. My results were consistent with this hypothesis and two main findings
summarize my results. First, repeated morphine administration exacerbated acidinduced stretching and acid-induced depression of ICSS when lactic was administered
during morphine abstinence. Second, morphine at a dose of 1.0 mg/kg was effective to
block acid-induced stretching and acid-depressed ICSS in the repeated-vehicle treated
group. However, repeated morphine administration produced tolerance to the
antinociceptive effect of 1.0 mg/kg morphine in the assay of acid-stimulated stretching,
but not in the assay of acid-depressed ICSS.
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Figure 6.1

Figure 6.1. Effects of different acute treatments on stretching behavior in rats
treated chronically with vehicle or morphine. Subjects were treated repeatedly with
saline (open bars) or morphine (filled bars). Horizontal axis: acute treatment of 1.0
mg/kg morphine or vehicle + 1.8% lactic acid or vehicle. Vertical axis: number of
stretches during 30-min observation period. Two-way ANOVA showed that there was
significant main effect of acute treatment [F=45.4; P<0.001], significant main effect of
chronic group [F=34.1; P<0.001], and significant treatment x chronic group interaction
[F=9.7; P<0.001]. * Asterisks indicate treatments that were significantly different from
vehicle + vehicle within the same group. $ Dollar signs indicate treatments that were
significantly different from vehicle + 1.8% lactic acid within the same group. # indicates
significance between groups after the same treatment.
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Figure 6.2

Figure 6.2. Effects of different acute treatments on ICSS behavior in rats treated
chronically with vehicle or morphine. Subjects were treated repeatedly with saline
(open bars) or morphine (filled bars). Horizontal axis: acute treatment of 1.0 mg/kg
morphine or vehicle + 1.8% lactic acid or vehicle. Vertical axis: percent baseline number
of stimulations per component. Two-way ANOVA showed that there was a significant
main effect of acute treatment [F=11.8; P<0.001], no significant main effect of chronic
group [F=1.2; P=0.281], and no significant treatment x chronic group interaction [F=1.6;
P=0.214]. * Asterisks indicate treatments that were significantly different from vehicle +
vehicle within the same group. $ Dollar signs indicate treatments that were significantly
different from vehicle + 1.8% lactic acid within the same group.
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Table 6.1. Summary table representing the daily treatments for each group in the
study. Morphine doses are shown in mg/kg. “Test” indicates a treatment with (1)
morphine vehicle + acid vehicle, (2) morphine vehicle + 1.8% lactic acid, (3) 1.0 mg/kg
morphine + acid vehicle, or (4) 1.0 mg/kg morphine + 1.8% lactic acid. Subjects in the
chronic morphine group also received a supplemental treatment of morphine at the end
of the test session on that day to maintain the total dose at 10 mg/kg/day. The chronic
vehicle group did not receive any supplemental injections on test days.

Day

Chronic vehicle group

Chronic Morphine Group

1-2

Daily treatment
Saline

Daily treatment
3.2 morphine

Supplemental treatment
N/A

3-4

Saline

5.6 morphine

N/A

5-7

Saline

10 morphine

N/A

8

Test

Test

9-10 morphine

9

Saline

10 morphine

N/A

10

Test

Test

9-10 morphine

11

Saline

10 morphine

N/A

12

Test

Test

9-10 morphine

13

Saline

10 morphine

N/A

14

Test

Test

9-10 morphine
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CHAPTER SEVEN
Discussion

7.1. General summary
This project tested a series of independent variables to evaluate effects of mu
opioid receptor agonists on ICSS. Some of these independent variables include drug
efficacy, dose, pretreatment time, and repeated administration of morphine. Opioids’
effects on ICSS were evaluated in two phases:
1) Phase 1: Experiments were conducted in the absence of any noxious
stimulus.
2) Phase 2: opioid effects were evaluated in the presence of an acute visceral
noxious stimulus (intraperitoneal injection of dilute lactic acid)

The discussion that follows will describe and interpret mu agonist effects on
ICSS. As a prelude to this discussion, it should be noted that our “frequency-rate” ICSS
procedure used a wide range of brain stimulation frequencies to maintain a wide range
of baseline behavioral rates. Drug effects on these different baseline rates of behavior
will be described using two terms. “Rate-decreasing effects” describes treatment-
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induced decreases in high rates of ICSS maintained by high brain stimulation
frequencies. “Rate-increasing effects” will be used to describe treatment-induced
increases in low rates of ICSS maintained by low brain stimulation frequencies.
Importantly, both effects can occur simultaneously, and these two effects can be
differentially modulated.
Phase 1. Four major findings summarize data from this phase. First, effects of acute
opioid administration in naïve subjects are efficacy dependent, such that high-efficacy
ligands produce dose-dependent rate-decreasing effects, while low-efficacy ligands
produce mild and inconsistent rate-increasing effects and antagonize the ratedecreasing effects of high-efficacy agonists. Second, repeated administration of
morphine produces tolerance to its rate-decreasing effect and cross-tolerance to the
rate-decreasing effects of other high-efficacy ligands, such as methadone and fentanyl.
Third, repeated morphine administration does not produce clear tolerance to its rateincreasing effects, but rather enhances the expression of abuse-related rate-increasing
effects of high- and low-efficacy mu agonists. Finally, abstinence from morphine after
repeated administration induces withdrawal-related decrease in ICSS. Collectively,
these findings suggest that mu opioid agonist effects on ICSS are dependent on history
of opioid administration, and abuse liability of these drugs is enhanced after repeated
opioid administration.

Phase 2. Results from this phase can be summarized into three major findings. First,
mu receptor agonists blocked pain-induced depression of ICSS; there was little effect of
efficacy between drugs with the exception that high-efficacy drugs produced inverted U-

- 119 -

shaped dose-effect curves, and also tended to be more potent to block acid-depressed
ICSS compared to acid-stimulated stretching. Second, both the high-efficacy agonist
methadone and the low-efficacy agonist nalbuphine retained their antinociceptive
effects in the presence of a high intensity noxious stimulus, although the potency of both
drugs was reduced. Third, morphine antinociception was resistant to tolerance in the
assay of acid-depressed ICSS in comparison to the assay of acid-stimulated stretching.
Taken together, these findings suggest that mu agonists across a broad range of
efficacies produce antinociception in this assay of acid-depressed ICSS, and that
morphine antinociception in this assay is resistant to tolerance. The potential
relationship will be discussed below between (a) increased expression of ICSS
facilitation after repeated morphine, and (b) resistance to antinociceptive tolerance in
the assay of acid-depressed ICSS.

7.2. Effects of acute morphine (phase 1)
Results in chapter 2 agree with previous studies in finding that acute morphine
effects on ICSS can display a biphasic time course characterized by an initial decrease
followed by a subsequent increase in rates of ICSS (Adams et al., 1972; Lorens and
Mitchell, 1973; Bermudez-Rattoni et al., 1983). A similar biphasic time course was also
produced by the mu agonist heroin (Koob et al., 1975). In these earlier studies, baseline
responding was maintained at relatively stable rates by constant intensities and
frequencies of electrical stimulation. This study extends these findings by using a
‘frequency–rate’ procedure that generated a wide range of baseline response rates to
systematically examine the rate dependency of acute morphine effects. This procedure
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confirmed that early rate-decreasing effects of morphine were greatest for high baseline
response rates maintained by high frequencies of stimulation, whereas later rateincreasing effects of morphine were most prominent for low to intermediate response
rates maintained by low-to-intermediate frequencies of stimulation. Additional
discussion of rate dependence is provided below.
In chapter 2, low morphine doses (1–3.2 mg/kg) produced small but significant
increases in low ICSS rates during the first 30 min after morphine injection. This agrees
with the finding that similarly low morphine doses at similarly short pretreatment times
produced facilitation of ICSS in some (Kornetsky and Esposito, 1979; Carlezon and
Wise, 1993; Jha et al., 2004) but not all (Stratmann and Craft, 1997; Pereira Do Carmo
et al., 2009) studies that focused on low baseline ICSS rates maintained by threshold
frequencies or intensities of stimulation. However, any facilitation of ICSS observed
early in the time course of low-dose acute morphine is weaker and less consistent than
the more robust facilitation of ICSS observed later in the time course of larger morphine
doses (chapter 2; (Easterling and Holtzman, 1997; O'Neill and Todtenkopf, 2010)).
The biphasic time course of acute morphine effects on rates of ICSS is similar to
the biphasic time course of morphine effects on rates of locomotor activity in rats (Vasko
and Domino, 1978; Craft et al., 2006). For example, morphine (1–10 mg/kg
subcutaneously) produced initial dose-dependent decreases (approximately 30–90 min
after injection) followed by later increases (approximately 2–5 h after injection) in
horizontal activity in male rats relative to their saline-treated controls (Craft et al., 2006).
Moreover, the time course of morphine-induced depression of ICSS and locomotion
corresponds to the time course of morphine-induced depression of some other
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behaviors, such as thermal nocifensive behaviors in tail flick and hot-plate assays
(Cicero et al., 1996; Cicero et al., 1997), and a stimulation of pain-related behaviors
may emerge after antinociceptive effects have dissipated (i.e. opioid-induced
hyperalgesia) (Chu et al., 2008). Taken together, these findings provide evidence of
relatively broad behavioral depressant effects of acute morphine that may be followed
by later behavioral stimulant effects. Factors that underlie the emergence of morphineinduced stimulant effects are not known. One possibility is that acute tolerance develops
to behavioral depressant effects, thereby unmasking behavioral stimulant effects.
Section 7.4 discusses this possibility based on data collected from chronic studies.

7.3. Effects of drug efficacy (phase 1)
Drugs with varying efficacies at mu receptors can be tested to provide insight into
the efficacy requirements of different effects produced by mu agonists. For example,
low-efficacy mu agonists such as nalbuphine often produce antinociception against lowbut not high-intensity noxious thermal stimuli, whereas higher efficacy mu agonists such
as morphine and methadone are more likely to produce antinociception against both
low- and high-intensity noxious stimuli (Morgan et al., 1999; Negus and Mello, 1999;
Cook et al., 2000). Such data provide one source of evidence to suggest that
antinociception against low-intensity noxious stimuli in conventional assays of painstimulated behavior has lower efficacy requirements than antinociception against highintensity noxious stimuli.
In chapter 3, the low-efficacy mu agonist nalbuphine facilitated ICSS across a
broad range of doses but produced little or no depression of ICSS, whereas the higher
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efficacy mu agonist methadone produced biphasic facilitation and depression of ICSS.
These findings are superficially consistent with lower efficacy requirements for
facilitation than depression of ICSS. However, these results were collected in opioidexperienced rats, albeit using a twice-per-week testing regimen intended to minimize
opioid tolerance. Given the known potential for opioid exposure to attenuate ICSSdepressing effects as shown in Chapter 2, a follow-up study was conducted with
nalbuphine and methadone in opioid-naïve rats. Methadone was more potent in
depressing ICSS and both drugs were less effective in facilitating ICSS in opioid-naïve
than opioid-experienced rats. The differences in methadone effects between opioidnaïve and opioid-experienced rats suggests that even intermittent opioid exposure
associated with twice-per-week testing was sufficient to produce tolerance to ICSS
depression similar to that observed with more intensive daily regimens of morphine
treatment (Chapter 2). Moreover, these results suggest that opioid exposure also
augments expression of rate-increasing effects produced by low-efficacy mu agonists
like nalbuphine that do not reliably facilitate ICSS in naïve rats. Overall, the limited and
unreliably dose-dependent ability of nalbuphine to facilitate ICSS in rats with little or no
history of opioid exposure fails to support the hypothesis that opioid-induced facilitation
of ICSS has lower efficacy requirements at mu receptors than opioid-induced
depression of ICSS. This conclusion was also supported by other experiments
conducted in the same laboratory, which showed similar sensitivity of morphine-induced
rate-increasing and rate-decreasing effects to antagonism by the irreversible mu
antagonist ß-funaltrexamine (Altarifi et al., 2012).
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7.4. Effects of repeated morphine administration (phase 1)

7.4.1. Effects of morphine during repeated administration of morphine
In chapter 2, repeated morphine treatment reduced the initial rate-decreasing
effects of morphine while producing earlier expression of rate-increasing effects. The
onset of tolerance to the rate-decreasing effects of morphine seemed to be rapid.
Informal analysis of data obtained during the acute-dosing phase of the study did not
reveal a systematic effect of the dose order on rate-increasing versus rate-decreasing
morphine effects (data not shown); however, ICSS was not significantly altered 30 min
after 3.2 mg/kg morphine during the acute phase of the study but was significantly
facilitated 30 min after administration of the same dose on day 1 of the chronic dosing
phase of the study. This suggests that morphine exposure associated with intermittent
dosing to determine the dose-effect curve during the acute-dosing phase of the study
was sufficient to produce some degree of tolerance to the rate-decreasing effects of
morphine, and the extent of this tolerance became more pronounced during the chronicdosing phase. This agrees with the effects of repeated morphine from studies that used
simpler ICSS procedures in which relatively constant baseline response rates were
maintained by constant magnitudes of brain stimulation (Lorens and Mitchell, 1973). For
example, Lorens and Mitchell 1973 administered morphine doses of 5, 10, or 20 mg/kg
daily for 5 days in rats trained to respond for a single magnitude of brain stimulation. On
the first day of treatment, all three doses produced initial rate-decreasing effects
followed by later rate-increasing effects. However, as early as the third day of treatment,
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doses of 5 and 10 mg/kg morphine ceased to produce rate-decreasing effects, and rateincreasing effects occurred with an earlier onset and similar duration of action. These
results also agree with studies using more sophisticated procedures that showed
reductions in initial rate-decreasing effects and/or increased expression of rateincreasing effects during repeated morphine treatment (Carlezon and Wise, 1993;
Easterling and Holtzman, 1997; Craft et al., 2001). This study adds to this literature by
evaluating the effects of a broad range of morphine doses on responding maintained
across a broad range of ICSS rates. Finally, the tolerance to morphine-induced ratedecreasing effects produced by repeated morphine in assays of ICSS is qualitatively
similar to the rapid tolerance to morphine-induced rate-decreasing effects that develop
in assays of locomotor activity (Babbini and Davis, 1972; Vasko and Domino, 1978;
Smith et al., 2009).
A parsimonious interpretation of these data is that morphine effects on ICSS
reflect an integration of rate-decreasing and rate-increasing effects, and that tolerance
to rate-decreasing effects results in an unmasking of rate-increasing effects. The
mechanisms responsible for this tolerance are not known and may include processes of
either pharmacodynamic or behavioral tolerance (Smith, 1979; Negus et al., 2010). For
example, it is well-established that tolerance can develop at different rates to different
morphine effects, and this differential tolerance to behavioral effects is accompanied by
differential tolerance to intracellular signaling in different mu opioid receptor populations
in the brain. Thus, chronic morphine treatment selectively decreased mu agoniststimulated G-protein activation in brainstem nuclei (including dorsal raphe nucleus and
locus coeruleus) thought to contribute to rate-decreasing effects of opioids, but not in
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the forebrain structures (including NA and amygdala) thought to contribute to the
stimulant effects of opioids (Broekkamp et al., 1976; Sim et al., 1996). Overall, mu
receptor populations mediating abuse-related facilitation of ICSS may be more resistant
to tolerance during chronic opioid exposure than mu receptor populations mediating rate
suppression. Increased expression of morphine-induced stimulant effects may involve
not only a resistance to tolerance but also a sensitization of neural circuits that mediate
these effects. For example, a regimen of repeated morphine administration similar to
that used here increased expression of the GluR1 subunit of AMPA glutamate receptors
in rat ventral tegmental area, an effect that could increase sensitivity of ventral
tegmental area dopaminergic neurons to glutamatergic inputs (Fitzgerald et al., 1996).

7.4.2. Cross-tolerance between opioids on ICSS
Chapter 4 examined the impact of graded morphine exposure on changes in
ICSS produced by agonists with high efficacy (methadone), intermediate efficacy
(fentanyl) or low efficacy (nalbuphine) at mu opioid receptors. There were three main
findings. First, in agreement with previous results with morphine described in chapter 3,
the higher efficacy mu agonists methadone and fentanyl produced primarily ratedecreasing effects in opioid-naïve subjects, whereas the low-efficacy mu agonist
nalbuphine produced primarily rate-increasing effects that did not vary systematically as
a function of dose. Second, repeated morphine produced cross tolerance to the ratedecreasing effects and enhanced expression of the rate-increasing effects of all three
mu agonists. Lastly, the daily morphine dosing regimen used here produced withdrawalassociated decreases in baseline ICSS determined approximately 23 hrs after
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morphine. Repeated morphine also enhanced rate-decreasing effects of the antagonist
naltrexone. However, this evidence of opioid dependence and withdrawal was not
sufficient to account for enhanced expression of mu agonist-induced rate-increasing
effects. Taken together, these results provide further evidence to suggest that repeated
opioid exposure increases the degree to which mu agonists produce abuse-related
facilitation of ICSS.
Opioid effects in opioid-naïve rats. The constellation of rate-increasing and
rate-decreasing effects produced by methadone, fentanyl and nalbuphine in opioidnaïve subjects in this study agrees with effects reported previously for these and other
mu agonists that vary in efficacy at mu receptors (Chapter 3; Altarifi and Negus, 2011;
Altarifi et al., 2012). Specifically, rate-decreasing effects predominate for high-efficacy
agonists; lower efficacy agonists produce weaker and more variable evidence of rateincreasing and rate-decreasing effects; and antagonists such as naltrexone fail to alter
ICSS at doses that antagonize effects of mu agonists. The efficacy-dependent ratedecreasing effects of mu agonists in this ICSS procedure agree with the efficacydependent magnitude and/or variability in rate-decreasing effects of mu agonists in
other assays of responding maintained by other reinforcers (e.g. food) under other
schedules (Oliveto et al., 1991; Pitts et al., 1996). Moreover, in the ICSS literature,
drug-induced facilitation of ICSS is often interpreted as evidence of an abuse-related
effect, whereas drug-induced depression of ICSS is often interpreted as evidence of
abuse-limiting dysphoric effects or motor impairment (Carlezon and Chartoff, 2007).
From this perspective, the present results could be interpreted to suggest that abuselimiting dysphoric and/or motor effects often predominate over abuse-related rewarding
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effects of mu agonists in opioid-naïve rats. This finding in ICSS may be related to the
observation that mu agonists are often more efficacious to produce dysphoric subjective
effects and behavioral impairment than abuse-related euphoric effects in opioidnaïve/inexperienced human subjects (Lasagna et al., 1955; Walker et al., 2001).
Opioid effects in morphine-treated rats. Repeated morphine has been shown
previously to produce tolerance to the ICSS-decreasing effects of morphine (Lorens and
Mitchell, 1973; Altarifi and Negus, 2011), and the present study found that repeated
morphine also produced cross-tolerance to the ICSS-decreasing effects of the other mu
agonists methadone and fentanyl. This agrees with previous reports of morphineinduced cross tolerance to other effects of methadone and/or fentanyl, including their
rate-decreasing effects in assays of schedule-controlled responding for food
reinforcement (Picker et al., 1991; Hughes et al., 1995; Smith et al., 1997) or their
morphine-like discriminative stimulus effects (Young et al., 1991; Walker et al., 1997).
Nalbuphine produced only small and inconsistent rate-decreasing effects before
morphine treatment, and as a result, cross tolerance was difficult to assess.
Nonetheless, the complete absence of nalbuphine-induced rate-decreasing effects
during morphine treatment suggests that morphine also produced cross tolerance to
any rate-decreasing effects of nalbuphine. Previous studies have failed to reveal cross
tolerance between the rate-decreasing effects of morphine and nalbuphine in assays of
schedule-controlled responding for food (Oliveto et al., 1991; Picker and Yarbrough,
1991; Smith et al., 1997), but nalbuphine rate-decreasing effects in these studies
occurred only at high doses, were variable across subjects, and may have been
associated with precipitated withdrawal during morphine treatment (see below). The
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present findings agree with previous reports of cross tolerance between other effects of
morphine and nalbuphine, such as discriminative stimulus effects (Walker et al., 1997)
and thermal antinociceptive effects (Gringauz et al., 2001).
In addition to producing tolerance to mu agonist-induced rate-decreasing effects,
repeated morphine treatment also enhanced expression of mu agonist-induced
facilitation of ICSS. This agrees with previous studies reporting that repeated morphine
enhances expression of its own ICSS-facilitating effects (Carlezon and Wise, 1993;
Altarifi et al., 2012), and extends this phenomenon to other mu agonists with a broad
range of efficacies at mu receptors. As discussed above with morphine, unmasking of
the rate-increasing effect after selective tolerance to rate-decreasing effects and/or
sensitization to neural substrates that mediate rate-increasing effects are possible
explanations for the enhanced expression of abuse-related rate-increasing effects of
other mu agonists during morphine treatment. Regardless of the underlying mechanism,
these data suggest a shift in morphine effects that favors expression of abuse-related
rate-increasing effects relative to abuse-limiting rate-decreasing effects. This shift
apparent in ICSS may be related to the finding that regimens of mu agonist exposure
can also increase expression of abuse-related rewarding effects in preclinical assays of
place conditioning (Lett, 1989; Shippenberg et al., 1996), increase reinforcing effects in
preclinical assays of self-administration (Thompson and Schuster, 1964; Yanagita,
1978; Carrera et al., 1999; Negus and Rice, 2009), and increase expression of abuserelated subjective effects and reinforcing effects in humans (Comer et al., 2010; Cooper
et al., 2012).
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The regimen of repeated morphine treatment used in this study produced little
evidence of tolerance to mu agonist-induced ICSS facilitation, even when the daily
morphine dose was increased to 18 mg/kg/day. This dose was sufficient to produce
signs of morphine dependence (see below), but even the low-efficacy mu agonist
nalbuphine continued to produce significant ICSS facilitation across the entire dose
range tested. Indeed, the only evidence for tolerance to rate-increasing effects was that
a dose of 0.01 mg/kg fentanyl facilitated ICSS during treatment with 3.2 mg/kg/day
morphine but not during treatment with 18 mg/kg/day morphine. It is possible that more
intensive treatment regimens (e.g. higher morphine doses or longer treatment times)
may have produced tolerance to rate-increasing effects. However, the present results
suggest that mu agonist-induced facilitation of ICSS is relatively resistant to tolerance.

7.4.3. Role of morphine dependence and withdrawal
In addition to producing tolerance to morphine-induced rate-decreasing effects,
repeated morphine also produced dependence as indicated by dose-dependent
decreases in ICSS during spontaneous morphine withdrawal (figure 2.4; figure 4.1) and
during precipitated withdrawal after administration of the mu opioid receptor antagonist
naltrexone (figure 4.5). These findings agree with other studies reporting reductions in
ICSS during spontaneous or antagonist-precipitated morphine withdrawal (Schaefer and
Michael, 1983; Easterling and Holtzman, 1997; Liu and Schulteis, 2004). The absence
of clear somatic withdrawal signs during spontaneous withdrawal further suggests that
ICSS may be more sensitive than commonly assessed somatic signs to the impact of
opioid withdrawal.
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The withdrawal-associated depression of ICSS could be reversed by all three mu
agonists (chapter 4). However, three findings suggest that enhanced expression of mu
agonist-induced ICSS facilitation could not be attributed completely to reversal of
morphine withdrawal. First, this enhanced expression of ICSS facilitation was observed
during treatment with a lower dose of 3.2 mg/kg/day morphine, which did not produce
evidence of dependence or withdrawal. Second, during treatment with 18 mg/kg/day
morphine, nalbuphine reliably facilitated ICSS despite its simultaneous precipitation of
diarrhea, a common sign of opioid withdrawal. Lastly, the enhanced expression of
methadone- and nalbuphine-induced facilitation of ICSS was also observed more than 2
weeks after termination of repeated morphine, a time when signs of morphine
dependence and withdrawal had dissipated (figure 4.6).

7.5. Rate-dependency of morphine effect (phase 1)
“Rate-dependency” in behavioral pharmacology describes a phenomenon in
which the effect of a drug on the rate of a behavior varies systematically as a function of
the baseline, pre-drug rate of that behavior (Dews, 1958; Sanger and Blackman, 1976;
Dews, 1981). Rate-dependent effects of a given drug dose under FI schedules are
typically manifested as some degree of increase in low rates of behavior coupled with
smaller increases or with decreases in higher rates of behavior, and this relationship is
often displayed as a negatively sloped line on a graph that plots baseline rate on the
abscissa (usually expressed “log baseline rate”) as a function of rate after drug
administration on the ordinate (usually expressed as “log % baseline rate”) (Dews,
1964; Kelleher and Morse, 1968; McMillan, 1973; Sanger and Blackman, 1976). We
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found previously that abuse liability of monoamine releasers may be related to
expression of rate-dependent drug effects in assays of ICSS (Bauer et al., in press). A
key finding of the present study was that repeated morphine treatment increased the
rate dependence of morphine effects on ICSS. Early in the time course after acute
administration, morphine effects on ICSS displayed rate dependence only insofar as the
highest morphine dose (10mg/kg) decreased high ICSS rates maintained by high
frequencies of stimulation more than it decreased lower ICSS rates maintained by lower
frequencies of stimulation. This generally agrees with the rate dependence of acute
morphine effects in previous studies using other schedules of reinforcement and other
consequent stimuli. For example, morphine primarily decreased food-maintained
response rates maintained under different schedules of reinforcement in rats, and these
effects were rate-dependent insofar as high rates were decreased more than low rates
(Thompson et al., 1970). Acute morphine has been reported to increase low response
rates maintained during the early segments of fixed-interval schedules or under a
differential-reinforcement-of-low-rates- of-responding schedule (McMillan and Morse,
1967; Ford and Balster, 1976), although these rate-increasing effects may be
dependent on the consequent stimulus (McKearney, 1980). In chapter 2, low doses of
acute morphine also occasionally increased response rates, but these effects were not
rate-dependent and were most evident for intermediate ICSS rates maintained by
intermediate frequencies of brain stimulation. Morphine exposure associated with longer
pretreatment times or with repeated morphine treatment produced qualitative and
quantitative changes in the rate dependency of morphine effects, increasing the
correlation coefficients and slopes of rate-dependency plots and shifting these plots
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vertically upward such that morphine primarily increased low rates of ICSS rather than
decreasing high rates of ICSS. In this regard, morphine effects after repeated morphine
qualitatively resembled rate-dependent effects of central nervous system stimulants
such as amphetamine (Sanger and Blackman, 1976; Do Carmo et al., 2009; Bauer et
al., in press). To our knowledge, this is the first study to report a change in ratedependent effects of morphine or any other mu opioid receptor agonist produced by
repeated drug treatment. Moreover, insofar as stimulant-like and rate-dependent
facilitation of ICSS is predictive of abuse liability, these findings are consistent with the
hypothesis that the abuse liability of morphine increases with repeated exposure (Negus
et al., 2006; Bauer et al., in press).

7.6. Effects of opioids on acid-depressed ICSS (phase 2)
Morphine and other mu agonists are potent analgesics, and they are used for
severe and chronic pain conditions. In this project, these drugs were tested in an assay
of pain-depressed behaviors in rats that was used previously to study morphine (Pereira
Do Carmo et al., 2009), and as in that original study, results were compared to results
from an assay of pain-stimulated behavior. Specifically, intraperitoneal injection of 1.8%
lactic acid served as an acute noxious visceral stimulus to stimulate a stretching
response and depress ICSS. The original hypothesis was that mu opioid agonists,
which are effective clinically to treat pain, will block acid-stimulated stretching and acidinduced depression of ICSS.
In this study, all mu opioid agonists produced a dose-dependent decrease in
acid-stimulated stretching. The antinociceptive effects observed in this assay were
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similar to antinociceptive effects of mu opioid agonists in many other assays of painstimulated behavior, and such data have often been interpreted as evidence of
analgesic effects of mu agonists. However, exclusive reliance on pain-stimulated
behaviors to evaluate effects of opioids or other candidate analgesics is problematic for
several reasons (Negus et al., 2006). Most importantly, drug-induced decreases in painstimulated behavior can be produced not only by a selective reduction in sensory
sensitivity to the noxious stimulus (i.e. true analgesia) but also by nonselective effects
such as motor impairment (resulting in “false positive” effects). Insofar as mu agonists
are known to function as clinically effective analgesics under a wide variety of
conditions, including the treatment of visceral pain (Yuan et al., 2010; Carter and Green,
2011; O'Connor and Rao, 2012), we anticipated that mu agonists would also produce
antinociception in assays of pain-depressed behavior.
Accordingly, drugs with variable efficacy at the mu receptor were tested to
determine their potency to block acid-induced depression of ICSS. At first, all drugs
were tested for their antinociceptive effect as a pretreatment to intraperitoneal injection
of 1.8% lactic acid. During this phase, all mu agonists produced dose-dependent
blockade of acid-induced depression of ICSS. This is consistent with their efficacy to
block acid-stimulated stretching in this study. Also, my findings are consistent with the
ability of mu agonists to block many other examples of pain-depressed behavior
produced by several other types of pain manipulation, such as pain-depressed feeding,
and pain-depressed locomotion (Martin et al., 2004; Neubert et al., 2005; Neubert et al.,
2006). These findings suggest considerable generality in the ability of mu agonists to
block pain-related depression of behavior.
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High-efficacy agonists like methadone produced inverted U shaped dose-effect
curves such that peak blockade of acid-induced depression of ICSS was produced by
intermediate doses, whereas higher doses produced weaker acid blockade, perhaps
because rate-decreasing effects of the high-efficacy agonist limited expression of
antinociception. Moreover, high-efficacy agonists were generally more potent to block
acid-induced depression of ICSS than acid-induced stimulation of stretching.
Conversely, lower efficacy agonists produced only a monotonic and dose-dependent
blockade of acid-induced ICSS depression across a broad dose range, and these drugs
also tended to be less potent to block acid-induced depression of ICSS than acidinduced stimulation of stretching. These results show the potential for efficacydependent mu agonist effects in assays of pain-depressed vs. pain-stimulated behavior,
but further studies will be required to assess generality across other mu agonists and to
determine underlying mechanisms.
Phase two also included control experiments that examined effects of test drugs
administered alone in the absence of noxious stimulation (open bars in figures 5.3; 5.4;
5.5). Except for morphine, all drugs produced mild, but significant, facilitation of ICSS in
the absence of lactic acid, suggesting that these drugs may produce non-selective
facilitation of ICSS. These results may stand against their “selective” antinociceptive
effects after lactic acid administration. However, three findings suggest that mu agonist
blockade of acid-induced depression of ICSS was not due to non-selective facilitation of
ICSS. First, non-opioid analgesics that are used to reduce pain in humans, such as
NSAIDs, were also effective to block acid-induced depression of ICSS (Negus et al.,
2012). On the other hand, drugs that fail to produce analgesia in humans, such as
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kappa opioid receptor agonists, failed to block acid effects in this assay (Wadenberg,
2003; Negus et al., 2010; Negus et al., 2012). Second, all mu agonists were more
efficacious to block acid-induced depression of ICSS than to facilitate ICSS in the
absence of acid. For example, 0.1 mg/kg methadone produced a 20% increase in ICSS
compared to vehicle when given as a pretreatment to acid vehicle (open bars; figure
5.3). However, when the same dose was administered prior to 1.8% lactic acid, it
produced a 38% increase in ICSS compared to vehicle (filled bars; figure 5.3). This
suggests that non-selective facilitation is not sufficient to explain blockade of aciddepressed ICSS. Third, the magnitude of opioid-induced facilitation of ICSS in the
absence of acid (in these opioid naïve rats) is modest compared to other drugs, such as
stimulants. For instance, cocaine failed to block acid-induced depression of ICSS at
doses that significantly facilitated ICSS (Negus et al., 2012), and a high dose that did
block acid-induced depression of ICSS also produced more than a 50% increase in
ICSS in the absence of acid. Mu agonists did not produce the same profile as cocaine,
and all of them produced antinociception at doses that did not affect ICSS, or that only
mildly facilitated ICSS.
The ability of high-efficacy mu opioid agonists (methadone, fentanyl, and
hydrocodone) to facilitate ICSS under control conditions in figures 5.3 and 5.4 was
surprising and did not agree with previous findings shown in chapters 3 and 4, where
high-efficacy ligands tended to depress ICSS at high doses with little or no evidence of
ICSS facilitation at low to intermediate doses. Two factors may contribute to this
difference. First, although each drug was tested in a separate group of naïve rats, each
drug dose was given twice during phase 2, once prior to acid vehicle, and once prior to
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1.8% lactic acid, whereas each drug dose was administered only once during phase 1.
As shown in chapter 3, a history of intermittent opioid administration enhances the
expression of rate-increasing effects, and subjects in phase 2 received double the
injections that subjects in phase 1 were receiving. Second, subjects in phase 2 also
received intermittent exposure to a noxious stimulus of 1.8% lactic acid, which might
enhance the release of endogenous opioids (Kamata et al., 1986), and this in turn might
contribute to the enhancement of rate-increasing effects produced by exogenous mu
agonists.

7.7. Manipulation of noxious stimulus intensity (phase 2)
In the previous section, low- and high-efficacy mu opioid agonists were effective
to produce antinociception when 1.8% lactic acid was used as the noxious stimulus.
Preclinical research with assays of pain-stimulated behavior suggests that low efficacy
analgesics may become ineffective to induce antinociception when a high-intensity
noxious stimulus is used (Morgan et al., 1999; Negus and Mello, 1999; Cook et al.,
2000). Likewise, high efficacy mu agonists are preferred over low-efficacy ligands in
severe cases of pain (Prommer and Ficek, 2012). In the present study, using 5.6%
lactic acid was intended to increase the intensity of the noxious stimulus.
The failure of 5.6% acid to produce significant stimulation of stretching is
consistent with previous findings (Pereira Do Carmo et al., 2009), and this finding can
produce greater behavioral depression that reduces not only normally adaptive
behaviors such as locomotion, but also pain-stimulated behaviors (Stevenson et al.,
2009). On the other hand, lactic acid produced a concentration-dependent decrease in
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ICSS, and this is consistent with intensity-dependent effects of other noxious stimuli on
other pain-depressed behaviors such as food-maintained operant responding (Neubert
et al., 2005). Consequently, it was possible to test opioid antinociception in the assay of
acid-depressed ICSS but not in the assay of acid-stimulated stretching when the
noxious stimulus was 5.6% lactic acid.
The original hypothesis was that an increase in noxious stimulus intensity would
produce a greater decrease in the potency and/or maximal effect of a low-efficacy mu
agonist than of a high-efficacy mu agonist. This hypothesis was derived from principles
of receptor theory and from previous findings that related drug efficacy at the mu
receptor to the intensity of the noxious stimulus (for review; McCormack et al., 1998),
although all of these findings relied exclusively on assays of pain-stimulated behavior to
test antinociception. Figure 7.1 summarizes this theory of possible outcomes due to an
“efficacy X noxious stimulus intensity” interaction.
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Figure 7.1. Simplified cartoon summarizes the effect of noxious stimulus intensity
on two hypothetical drugs that differ in their intrinsic efficacy at the mu receptor. For
further clarification, “DRUG A” represents a high-efficacy ligand (e.g. methadone), and
“DRUG B” represents a low-efficacy ligand (e.g. nalbuphine). Low, Medium, and High
indicate the intensity of the noxious stimulus. Adapted from (McCormack et al., 1998).
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In agreement with the hypothesis, the maximally effective methadone dose
against 1.8% acid (0.1 mg/kg) lost its antinociceptive effect after increasing the acid
concentration, but 1.0 mg/kg methadone was effective. Similarly, the maximally effective
nalbuphine dose against 1.8% acid (1.0 mg/kg) also lost its antinociceptive effect at the
higher acid concentration, but a higher nalbuphine dose of 10 mg/kg was effective.
Overall, the increase in noxious stimulus intensity produced a 10-fold decrease in
methadone potency and larger 15-fold decrease in nalbuphine potency without reducing
the maximal effect of either drug (table 5.1). Taken together, these results support our
hypothesis of greater potency reductions for the low- vs. high-efficacy mu agonist;
however, the magnitude of the difference across drugs was modest especially if
compared to previous findings with assays of pain-stimulated behavior. For example,
Morgan et al. compared antinociceptive effects of morphine and the lower efficacy mu
agonist buprenorphine in Lewis rats tested with a warm-water tail-withdrawal assay
(Morgan et al., 1999). Both morphine and buprenorphine produced dose-dependent and
complete antinociception at a stimulus intensity of 50°C. Increasing the stimulus
intensity to 56°C reduced morphine potency by approximately 5-fold, but buprenorphine
potency was reduced more than 30-fold, and the maximal effect of buprenorphine was
also reduced. Thus, the increase in thermal stimulus intensity in that assay of painstimulated behavior resulted in greater dissociation in antinociceptive effects of high- vs.
low-efficacy mu agonists than the increase in chemical noxious stimulus intensity in the
present assay of pain-depressed behavior.
The reason for the small difference in effects of stimulus intensity on low- vs.
high-efficacy mu agonist antinociception is not known. One possibility is that opioid
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antionociception in this assay of pain-depressed behavior has a relatively low efficacy
requirement, such that relatively large increases in noxious stimulus intensity may be
required to reduce maximum effects even of low-efficacy agonists. Consistent with this
possibility, mu agonists are generally much more potent in this assay of acid-depressed
ICSS (e.g. morphine ED50=0.124 mg/kg SC) than in thermal nociceptive assays of
pain-stimulated behavior (e.g. morphine ED50=2.53 mg/kg IP in Lewis rats tested at
50°C; Morgan et al., 1999). In a related possibility, as mentioned in the section 1.5,
lactic acid releases free protons that activate TRPV1 receptors and/or acid sensing ion
channels located in the peritoneal region. The expectation is that an increase in acid
concentration from 1.8 to 5.6% will activate more receptors, and hence produces more
nociceptor activation. However, it is possible that 5.6% acid is not a high enough
stimulus to dissociate between high- and low-efficacy opioids in ICSS. As a suggested
future experiment, a higher acid concentration or a different noxious stimulus could be
used to dissociate between methadone and nalbuphine effects on pain-depressed
ICSS. One limitation, however, in using higher acid concentration is the possible lethal
outcomes, which limit the number of test sessions conducted for each rat.
In this study, both methadone and nalbuphine produced antinociception after
low- and high- acid concentrations. Due to their sedative effects, high-efficacy ligands
produce a greater depression in behavior than low-efficacy mu agonists such as
locomotion or operant responding. This was observed in this study during phase 1,
where methadone but not nalbuphine produced dose-dependent rate-decreasing effects
in ICSS in naïve subjects (figure 3.3), and during phase 2 after high doses of
methadone, fentanyl, and morphine. In pain-stimulated behaviors, it is possible that
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high-efficacy ligands produce antinociception during high-noxious stimulus intensity
through “true” analgesia, or through a general decrease in behavior (false positive), or
both. The same concept does not apply to assays of pain-depressed behavior, such
that increasing the dose of the high-efficacy ligand will recruit some of their ratedecreasing effects, and this may obscure analgesic efficacy.
A suggested experiment to further dissociate between low- and high-efficacy mu
agonists in assays of pain-depressed ICSS is by inducing tolerance to the ratedecreasing effects by repeated administration of a mu agonist, such as morphine. As
discussed during phase 1, repeated morphine produced tolerance to the ratedecreasing effects of high-efficacy mu agonists. Also, repeated morphine did not
produce tolerance to their rate-increasing effects, and in fact, it enhanced expression of
rate-increasing effects produced by both low- and high-efficacy mu agonists. Repeated
morphine can produce desensitization of mu receptors at different brain areas (Sim et
al., 1996). Thus, by decreasing the total number of functional mu opioid receptors in the
brain, it is possible to dissociate between the low- and high-efficacy ligands to produce
antinociception in assay of pain-depressed ICSS. Consequently, antinociceptive effects
of methadone and nalbuphine could be determined in the presence and absence of
1.8% lactic acid in rats that were treated with chronic morphine. Since a) high-efficacy
ligands are effective to treat severe pain in the clinic, and b) they are also effective to
produce antinociception is assays of pain-stimulated behaviors during high-noxious
stimulus intensities in preclinical studies, I predict that methadone will maintain its
efficacy to produce antinociception in the assay of acid-depressed ICSS, while the
antinociceptive effects of nalbuphine will be more sensitive to repeated morphine
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treatment and will not block acid-induced depression of ICSS under the same
conditions.

7.8. Morphine antinociception after repeated administration (phase 2)
Chapter 6 tested the antinociceptive effects of morphine in acid-stimulated
stretching and acid-depressed ICSS after repeated chronic morphine administration.
One possibility for opioid-induced antinociception is that many drugs, including highefficacy mu agonists, can produce behavioral depressant effects that might augment
apparent antinociception in assays of pain-stimulated behavior (in which antinociception
is indicated by a depression of the target behavior). On the other hand, behavioral
depressant effects could actually oppose and limit expression of antinociception in an
assay of pain-depressed behavior (in which antinociception is indicated by increases in
the target behavior). During phase 1, repeated morphine produced tolerance to its own
rate-decreasing effects. If rate-decreasing effects contribute to morphine-induced
antinociception in assays of pain-stimulated behavior, then repeated morphine might
also produce tolerance to morphine effects in these assays. Conversely, if ratedecreasing effects do not contribute to morphine antinociception in assays of paindepressed behavior, then repeated morphine might not produce tolerance to morphine
antinociception in these assays; rather, repeated morphine might even enhance
antinociception in these assays by producing tolerance to rate-decreasing effects that
initially oppose and limit expression of antinociception. Thus, the hypothesis was that
morphine would maintain or increase its antinociceptive potency in the assay of acidinduced depression of ICSS, but that tolerance would develop to morphine
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antinociception in the assay of acid-stimulated stretching. Results from this study agree
with this hypothesis.
The development of tolerance to the antinociceptive effect of morphine in acidstimulated stretching is consistent with previous reports of opioid antinociceptive
tolerance in acid-stimulated stretching and other assays of pain-stimulated behavior (Su
et al., 2000; Dong et al., 2006; Trang et al., 2009). On the other hand, morphine
antinociception was resistant to tolerance in the assay of acid-depressed ICSS. This is
the first evaluation of effects produced by repeated morphine in an assay of paindepressed behavior. However, these results with morphine are similar to previous
findings with the delta agonist SNC80, showing that SNC80 pretreatment produced
acute tolerance to the antinociceptive effects of SNC80 in the assay of acid-stimulated
stretching but actually enhanced expression of SNC80 antinociception in the assay of
acid-depressed ICSS (Negus et al., 2012). These data suggest that morphine
antinociception is more vulnerable to tolerance in the assay of acid-stimulated stretching
than in the assay of acid-depressed ICSS.
The development of tolerance depends on the drug that is administered
chronically, the daily-injection dose and treatment regimen, and the duration of repeated
treatment. In this study, escalating doses of morphine were administered chronically for
1 week, and this regimen was sufficient to induce tolerance in acid-stimulated
stretching. Repeated morphine administration enhances the expression of abuserelated rate-increasing effects of morphine (Altarifi and Negus, 2011; Altarifi et al.,
2012), and this is not likely to account entirely for tolerance-resistance in the assay of
acid-depressed ICSS for two reasons. First, the chronic morphine regimen used in the
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antinociceptive tolerance study involved the administration of lower morphine doses for
a shorter period of time compared to the regimen used in phase one (10 mg/kg/day for
7 days compared to 3.2-18 mg/kg/day for 28 days, respectively), and hence, less
enhancement to the rate-increasing effect of morphine compared to phase 1. Second,
1.0 mg/kg morphine was the dose to produce antinociception in both groups, and this
dose produced mild facilitation of ICSS in the chronic morphine treated group (16%
increase versus acid vehicle). However, the same dose facilitated ICSS by 42% (versus
acid alone) when administered prior to 1.8% acid.
It is possible that morphine antinociception in pain-stimulated stretching and aciddepressed ICSS is mediated through distinct mu opioid receptor populations that may
respond differentially to chronic morphine. For example, repeated morphine
administration produces desensitization (Ferguson, 2001) and downregulation (Kieffer
and Evans, 2002) of the mu opioid receptor, and chronic morphine treatment selectively
decreased mu agonist-stimulated G-protein activation in brainstem nuclei but not in the
forebrain structures (including NA and amygdala) thought to contribute to the stimulant
effects of opioids (Sim et al., 1996). Thus, it is possible that morphine-induced
antinociception in acid-depressed ICSS is mediated through these desensitizationresistant receptors in the forebrain structures.
The absence of tolerance development to morphine in the assay of aciddepressed ICSS is paralleled by clinical findings indicating that opioids can maintain
analgesic efficacy for treatment of chronic and severe pain (Watson, 2012). Tolerance is
defined as a decrease in subject`s reaction to a specific drug or concentration, that
requires an increase in drug concentration to achieve the same desired effect.
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Tolerance to a drug effect may develop due to pharmacological reasons (such as
receptor desensitization), or pathological reasons (such as disease progression). Many
clinical studies showed that subjects who are maintained on relatively constant doses of
opioids in healthy individuals (Cooper et al., 2012) as well as in patients who suffer from
chronic pain (Cowan et al., 2001) do not show any signs of analgesic tolerance.
Although opioid dose escalation is necessary in some cases to maintain analgesic
effectiveness of opioids (Collett, 1998), this loss of analgesia is often related to factors
other than pharmacological tolerance, including disease progression (Portenoy, 1994;
Portenoy and Savage, 1997).
A final interesting finding in chapter 6 is the enhancement of stretching and
exacerbation (although not significant compared to control group) of acid-induced
depression of ICSS in the repeated morphine treated group. This is qualitatively similar
to hyperalgesia that has been shown to develop in other preclinical assays such as tail
flick and paw withdrawal after repeated morphine treatment (Dong et al., 2006; Ross et
al., 2012; Wei and Wei, 2012). Also, this repeated morphine-induced hyperalgesia was
also reported in clinical settings, where patients receiving opioids for the treatment of
pain may actually become more sensitive to pain (De Conno et al., 1991; Chu et al.,
2008). In the current study, morphine, lactic acid, or their vehicles were administered 24
hrs after the last daily morphine injection on the previous day. Subjects during this
period are possibly in a spontaneous-withdrawal period. Although the direct mechanism
of such pain-exacerbation is not exactly known, multiple molecular mechanisms may be
involved in such morphine-induced hyperalgesia.
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One possibility for this morphine-induced hyperalgesia is the enhancement of
TRPV1 channel current during repeated morphine treatment, as shown previously by
Ross et al 2012 (Ross et al., 2012). In the same study, they also showed that repeated
morphine administration is associated with hyperexcitability and functional remodeling
of sodium channels in sensory neurons. Another possibility is that repeated morphine
treatment may activate the descending pain facilitation arising in the RVM (Vanderah et
al., 2001). A final possibility is an alteration in opioid receptor signaling after chronic
opioid administration, such that there is a shift in opioid receptor G-protein signaling
from predominantly Gi/o inhibitory to Gs stimulatory following chronic in vivo morphine
exposure (Crain and Shen, 2000; Gintzler and Chakrabarti, 2000).

7.9. Conclusions and future directions
The main purpose of the above studies was to validate intracranial selfstimulation as an assay of pain-depressed behavior in preclinical research. The goal
was to find a novel animal model to measure pain-related changes in behavior in
preclinical research, which may generate better predictive validity outcomes to the
clinic. Morphine and other opioids were tested in these studies due to their known
analgesic efficacy in the clinic. Opioid pharmacology was studied in ICSS, and in an
assay of pain-stimulated behavior. The author predicts that assays of pain-depressed
behavior in animal research may provide a better “translational” tool to examine
analgesic properties of candidate drugs in animals. A good analgesic would block pain
in both assays, and may also be less susceptible to analgesic tolerance after chronic
administration. By using these assays of pain-stimulated and pain-depressed behavior
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and comparing effects of novel drugs to effects of opioid analgesics, it may be be
possible to identify new candidate analgesics that have less abuse-potential than
opioids (i.e. do not facilitate ICSS).
One limitation for using ICSS as a behavioral baseline in assays of paindepressed behavior is its sensitivity to stimulant effects of test drugs. Although this
assay has been useful to test abuse-related stimulant effects of new drugs, drugs that
produce non-selective facilitation of ICSS in the absence and presence of noxious
stimulus may fail to produce analgesia in humans. Thus, one suggested future
experiment is to investigate other behavioral baselines that may be less susceptible to
false-positive results, such as pain-depressed feeding and pain-depressed social
interaction. Another possible future direction is to test different types of pain modalities
that would be more clinically relevant, such as cancer pain and chronic pain.
Finally, a good strategy to enhance pain management is either to find alternative
analgesics to the ones that are currently used in the clinic, or to minimize the
disadvantages of currently used analgesics. Opioids are widely used in the clinic, but
they also have a high abuse potential. The above studies enhanced our knowledge of
some of the factors that could possibly be involved in opioid addiction. Future studies
could build on this information by seeking strategies to retain analgesic effects of mu
agonists while reducing abuse liability. For example, delta-opioid agonists (such as
SNC80) showed promising results to produce antinociceptive effects in assay of paindepressed behavior with less abuse-liability compared to mu agonists. These drugs
could potentially replace or minimize the dose required of mu opioid agonist to produce
clinical analgesia.
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2012)
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College on Problems of Drug Dependence (CPDD)
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International Narcotics Research Conference (INRC)
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2011-present
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March, 2013
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